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Rabbit	 Sigma-Aldrich	 1:5000	(WB)	 IgG	 A8967	
Anti-cortactin	 Mouse	 Millipore	 1:1000	(WB)	 IgG	 05-180	










Anti-LAMP1	 Rabbit	 Abcam	 1:110	(ICC)	 IgG	 ab24170	








Rabbit	 Millipore	 1:500	(WB)	 IgG	 AB3795	



































































































Complementary	DNA	 Backbone	 Tag/Reporter	 Cloning	sites	
APPWT	 pcDNA3.1	 pIRES-mCherry	 3’	SacII	5’		NheI	











































































































































Extension	 70°C	for	10s/kb	 70°C	for	15s/kb	 70°C	for	20s/kb	 70°C	for	25s/kb	
Final	extension	 70°C	for	4	minutes	
Cooling	 15°C	for	10	minutes	
	
4.3 CONSTRUCT	CLONING	
4.3.1 PCR	product	purification	
	
Agarose	gels	(0.8%	or	1.5%)	were	used	to	resolve	digested	PCR	products	and	vectors	for	screening	of	
positive	clones.	Molecular	biology	grade	agarose	(Sigma)	was	dissolved	in	0.5x	TAE	buffer	whilst	
heating.	Once	cooled	to	approximately	50°C,	ethidium	bromide	was	added	at	a	final	concentration	
of	0.5μg/ml	and	the	solution	was	poured	into	a	gel	mould	with	a	comb	to	set.	DNA	samples	were	
mixed	with	6x	loading	dye	(New	England	Biolabs)	to	a	final	concentration	of	1x	and	5μl	loaded	into	
wells	alongside	3μl	Hyperladder	(Bioline).	Gels	were	run	using	Mupid-eXu	gel	apparatus	for	30	
minutes	at	a	constant	135	V	in	0.5x	TAE	buffer	and	bands	detected	on	an	ultra-violet	(UV)	
transilluminator.		
	
	
	
55 
	
4.3.2 Restriction	digests	
	
Restriction	digests	were	set	up	with	1x	NEB	buffer	1-4	depending	on	enzyme	activity	compatibility	in	
100μl	total	volume.	1-5μg	plasmid	DNA	or	PCR	product	was	incubated	with	20U	of	each	restriction	
enzyme	at	37°C	for	2	hours.	20U	Calf	intestinal	alkaline	phosphatase	(CIP)	was	added	to	host	plasmid	
digestion	mixtures	to	catalyse	the	removal	of	5’	phosphate	groups	from	the	host	DNA,	thus	
preventing	re-ligation.	Products	were	purified	and	digestion	validated	by	running	on	agarose	gel.		
	
4.3.3 Ligation	
	
5μl	of	purified	DNA	was	run	on	agarose	gel	to	determine	a	suitable	vector:insert	ratio	for	ligation.	
Typically,	a	1:3	molar	ratio	was	used	to	mix	vector	and	insert.	1	volume	of	insert	and	vector	was	
added	to	1	volume	Takara	T4	ligase	solution	1	(Biowhittaker)	and	ligation	was	left	for	1-2	hours	at	
room	temperature.	A	control	was	set	up	alongside	where	insert	was	replaced	with	ddH2O	to	
determine	the	level	of	spontaneous	re-ligation.	Ligation	reactions	were	then	transformed	as	
described	in	3.2.1.	
	
4.3.4 Confirmation	of	cloning	
	
Small	scale	PCR	reactions	and	restriction	digests	were	used	for	screening	of	successful	clones.	DNA	
sequencing	was	performed	by	Eurofins	Genomics	using	stock	vector	primers	or	specifically	designed	
primers	corresponding	to	the	expected	sequence	of	the	insert.		
	
4.4 HEK293T	CELL	CULTURE	
4.4.1 Routine	culture	conditions	
	
All	cell	culture	methods	were	carried	out	in	laminar	fume	hoods	with	aseptic	technique.	HEK293T	
cells	were	cultured	in	complete	Dulbecco’s	Modified	Eagle	Medium	(DMEM).	Cells	were	cultured	in	
humidified	37°C	incubators	with	5%	CO2.		
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4.4.2 Cell	passage	
	
Cells	were	routinely	passaged	once	70-90%	confluent.	Media	was	aspirated	and	cells	were	washed	in	
8ml	pre-warmed	1x	distilled	phosphate	buffered	saline	(DPBS,	Sigma)	in	Cell	Culture	Sterile	Water	
(GE	Healthcare).	Cells	were	then	incubated	with	1ml	of	0.025%	trypsin-EDTA	for	2	minutes	at	room	
temperate	to	detach	adherent	cells.	Cells	were	diluted	in	10ml	complete	media,	pelleted	by	
centrifugation	at	2000	xg	for	2.5	minutes	and	re-suspended	in	10ml	complete	media	by	trituration.	
1ml	cell	suspension	was	transferred	into	a	new	T75	flask	containing	20ml	complete	media.		
	
4.4.3 Preparation	of	lentivirus	
	
4.4.3.1 HEK293T	cell	preparation	
	
Following	passage,	HEK	cells	were	counted	at	a	1:10	dilution	in	0.4%	trypan	blue	solution	using	a	
haemocytometer.	1.8	million	cells	were	plated	per	60mm	cell	culture	dish	containing	3ml	complete	
media	and	incubated	overnight	at	37°C	or	until	70%	competency	was	reached.		
	
4.4.3.2 HEK293T	cell	transfection	
	
A	three-plasmid	2nd	generation	lentiviral-producing	system	was	used	through	transfection	of	
HEK293T	cells.	DNA-DMEM	was	prepared	using	1ml	sterile-filtered	(45μm	nylon	mesh,	Fisher	
Scientific)	plain	DMEM,	4μg	XLG	viral	vector,	1μg	pMD2.G	(packaging	vector)	and	3μg	p8.91	(helper	
vector),	per	virus	to	be	made.	Polyethylenimide	(PEI)-DMEM	was	prepared	with	1ml	sterile-filtered	
plain	DMEM	per	transfection,	plus	1ml	extra,	combined	with	24μl	of	1mg/ml	PEI	for	each	ml	of	
DMEM.	This	was	mixed	by	inverting	and	left	to	equilibrate	at	room	temperature	for	2-3	minutes.	1ml	
of	the	PEI-DMEM	mixture	was	then	added	to	each	DNA-DMEM	mixture,	inverted	several	times	and	
left	at	room	temperature	for	30	minutes.	
HEK293T	cells	were	washed	once	with	3ml	pre-warmed	plain	sterile-filtered	DMEM,	then	media	
aspirated	and	2ml	of	the	transfection	mix	added.	Cells	were	incubated	for	4	hours	at	37°C	before	
replacing	media	with	3ml	pre-warmed	sterile-filtered	complete	DMEM.		
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4.4.3.3 Harvesting	lentivirus	
	
38-48	hours	post-transfection	the	virus-containing	media	was	centrifuged	at	4000	xg	for	10	minutes	
to	pellet	any	remaining	cell	debris.	The	resulting	supernatant	was	then	filtered	using	a	0.45μm	
membrane	pre-wetted	with	neuronal	plating	media.	Viruses	were	aliquoted	and	stored	at		
-80°C	until	use.		
4.5 ANIMAL	HUSBANDRY	
	
All	animal	experimental	procedures	were	performed	in	accordance	with	the	“Animals	Scientific	
Procedures	Act	1986”	and	the	University	of	Bristol	and	University	of	Exeter	policy	on	working	with	
animals.		
Wistar	rats	were	bred	at	the	University	of	Bristol	animal	facilities	and	kept	in	individually	ventilated	
cages	with	food	and	drink	available	ad	libitum.		
J20	and	wild-type	mice	were	bred	at	the	University	of	Exeter	animal	facilities	and	kept	in	individually	
ventilated	cages	under	a	12	h:12	h	light:dark	schedule	with	food	and	drink	available	ad	libitum.	
4.6 DISSOCIATED	RAT	EMBRYONIC	NEURONAL	CULTURE	
	
4.6.1 Glass	coverslip	preparation	
	
22mm	borosilicate	glass	coverslips	were	washed	in	100%	nitric	acid	overnight	with	gentle	shaking.	
Coverslips	were	then	washed	three	times	in	cell	culture	grade	water,	three	times	for	30	minutes	in	
cell	culture	grade	water	and	then	with	70%	ethanol	for	2	hours.	Another	three	30	minute	washes	in	
cell	culture	grade	water	followed	before	a	final	three	quick	washes.	Each	coverslip	was	placed	into	a	
35	mm	neuronal	cell	culture	dish	and	coated	with	1mg/ml	Poly-D-lysine	(PDL,	Sigma)	diluted	in	
borate	buffer	for	6-8	hours	at	37°C.	Following	three	washes	in	cell	culture	grade	water	and	one	wash	
in	plating	media,	on	the	day	of	dissection	plating	media	was	replenished	and	returned	to	37°C	until	
cell	seeding.		
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4.6.2 Dissection	
	
Primary	dissociated	hippocampal	and	cortical	cultures	were	prepared	from	embryonic	day	18	(E18)	
Wistar	rat	brains.	All	dissections	were	carried	out	according	to	a	modified	version	of	the	Brewer	
method	(Brewer	1997)	in	hank’s	balanced	salt	solution	(HBSS,	Gibco)	at	room	temperature.	Pregnant	
mothers	were	sacrificed	by	cervical	dislocation	under	Schedule	1	of	the	Home	Office	Animal	Welfare	
Regulations.	The	embryonic	sac	was	removed	and	placed	into	HBSS.	Embryos	were	removed	from	
the	embryonic	sac	and	decapitated	using	standard	dissection	tools.	Under	a	dissection	microscope,	
meninges	were	removed	and	cortices	and	hippocampi	excised.	These	were	then	washed	three	times	
in	10ml	HBSS	and	incubated	in	a	water	bath	at	37°C	with	1ml	0.025%	trypsin-EDTA	(pH	7.2)	in	10ml	
HBSS	for	9	minutes	or	3ml	0.025%	trypsin-EDTA	in	30ml	HBSS	for	12	minutes	for	hippocampi	and	
cortices	respectively.	Following	trypsinisation,	hippocampi	and	cortices	were	given	another	3	washes	
in	HBSS	and	a	wash	in	plating	media.	Hippocampi	and	cortices	were	triturated	in	1ml	and	5ml	of	
plating	media	and	cell	suspensions	were	then	diluted	to	total	volumes	of	5ml	and	20ml	respectively.	
The	cortical	cell	suspension	was	then	filtered	(70μm	nylon	mesh,	Fisher	Scientific)	to	remove	non-
dissociated	tissue.	Cells	were	counted	in	a	1:10	dilution	in	0.4%	trypan	blue	solution	using	a	
haemocytometer.		
	
4.6.3 Routine	culture	conditions	
	
Hippocampal	neurons	were	plated	at	200,000	cells	per	22mm	borosilicate	glass	coverslip	and	cortical	
neurons	were	plated	at	500,000	cells	per	PDL-coated	35mm	neuronal	cell	culture	dish.	Cells	were	
incubated	at	37°C	with	5%	CO2.	2-16	hours	after	plating,	media	was	replaced	with	feeding	media	and	
one	week	after	plating	1ml	feeding	media	treated	with	fluorodeoxyuridine	and	uridine	was	added	to	
inhibit	glial	growth.	Cells	were	then	incubated	until	required.		
	
4.6.4 Neuronal	transfection	
	
For	each	coverslip	1-2μg	DNA	and	2-3μl	Lipofectamine	2000	(L2K,	Invitrogen)	were	separately	
diluted	in	pre-warmed	neurobasal	medium	and	left	to	equilibrate	for	5	minutes.	The	L2K	was	then	
added	to	the	DNA	at	a	ratio	of	1.5μl:1μg,	vortexed	and	incubated	for	20	minutes	at	room	
temperature.	At	13	days	in	vitro	(DIV13)	hippocampal	neurons	were	washed	once	in	pre-warmed	
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plain	neurobasal	and	then	placed	into	pre-warmed	plain	neurobasal.	200μl	of	DNA-L2K	complex	was	
pipetted	dropwise	onto	each	coverslip	and	incubated	at	37°C	for	45	minutes.	Neurons	were	then	
returned	to	their	original	media	via	another	wash	in	pre-warmed	plain	neurobasal	and	used	for	
experiments	24-48	hours	later.	Transfection	efficiency	was	typically	around	10%.	
4.6.5 Neuronal	viral	infection	
	
Virus’	were	thawed	and	cortical	neurons	infected	at	DIV12-16.	For	each	35mm	neuronal	cell	culture	
dish,	a	maximum	of	450μl	lentivirus	was	added.	Neurons	were	then	left	at	37°C	for	4	days	until	lysis.	
	
4.7 WESTERN	BLOTTING	
4.7.1 Sample	preparation	
	
Cortical	neurons	were	lysed	in	250μl	1x	sample	buffer	and,	using	a	cell	scraper,	were	removed	from	
the	dish	surface	and	transferred	into	Eppendorf	tubes.	Samples	were	then	boiled	for	10	minutes	at	
95°C,	centrifuged	briefly	at	13,000	xg	and	stored	at	-20°C.	
	
4.7.2 SDS-PAGE	
	
Protein	separation	was	performed	by	sodium	dodecyl	sulphate	polyacrylamide	gel	electrophoresis	
(SDS-PAGE)	using	Bio-Rad	Mini-Protean	II	equipment.	8-10%	acrylamide	resolving	gels	(8-10%	(w/v)	
acrylamide,	375MM	Tris-HCl	pH8.8,	0.1%	(w/v)	SDS,	0.1%	(w/v)	ammonium	persulfate	(APS),	0.01%	
(v/v)	Tetramethylethylenediamine	(TEMED))	were	polymerised	at	room	temperature	in	1.5mm	glass	
plates	(Bio-Rad).	Different	percentages	of	acrylamide	were	used	in	resolving	gels	according	to	the	
molecular	weight	of	the	protein	being	analysed.	8%	gels	and	10%	gels	resolved	proteins	of	molecular	
weight	40-250	kDa	and	30-200	kDa	respectively.	5%	stacking	gel	(5%	(w/v)	acrylamide,	125mM	Tris-
HCl	pH6.8,	0.1%	(w/v)	SDS,	0.1%	(w/v)	APS,	0.01%	(v/v)	TEMED)	were	polymerised	on	top	of	the	
resolving	gel	and	set	with	a	10	or	15	well	gel	comb	to	create	sample	wells.		
Polymerised	gels	were	mounted	into	electrophoresis	tanks	(Biorad)	and	immersed	in	1x	SDS-PAGE	
running	buffer	(pH	8.3).	Samples	were	loaded	into	wells	alongside	3μl	molecular	weight	marker	
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(Page	RulerTM	Prestained	Protein	Ladder)	and	run	at	100	volts	through	the	stack	and	150-180	volts	
thereafter.		
	
4.7.3 Wet	transfer	
	
Following	electrophoresis,	resolved	proteins	were	transferred	onto	Polyvinylidene	Difluoride	(PVDF)	
membrane.	Membranes	were	activated	for	30	seconds	in	100%	methanol	and	then	stored	in	
transfer	buffer	(pH	8.3).	3MM	Whatman	blotting	paper	and	sponges	were	also	placed	in	transfer	
buffer.	The	gel	was	excised	from	the	glass	plates	and	stacking	gel	removed	before	assembly	of	the	
transfer	in	apparatus	according	to	manufacturer’s	instructions	(Bio-Rad).	The	transfer	system	was	
submerged	in	1x	transfer	buffer	and	run	for	60	minutes	at	400mA	with	buffer	agitation	and	cooling.			
	
4.7.4 Immunoblotting	
	
Following	transfer	onto	PVDF	membranes,	proteins	were	detected	via	immunoblotting.	Membranes	
were	removed	from	the	transfer	apparatus	and	placed	in	blocking	buffer	(pH	7.4)	(5%	(w/v)	milk	or	
5%	(w/v)	BSA	if	phospho-proteins	were	being	detected)	for	1	hour	on	a	shaker	at	room	temperature.	
Blocking	buffer	was	then	taken	off	the	membrane	and	replaced	with	primary	antibody	diluted	in	
blocking	buffer	(table	4-1)	overnight	at	4°C	with	shaking.	Membranes	were	washed	3	times	for	5	
minutes	in	1x	TBS-T	before	incubation	with	the	appropriate	horseradish	peroxidase	(HRP)	
conjugated	secondary	antibody	(table	4-2)	for	1	hour	at	room	temperature.	Membranes	were	then	
washed	4	times	for	10	minutes	in	1x	TBS-T	before	being	developed.		
	
4.7.5 Chemodetection	of	PVDF	membranes	
	
In	order	of	increasing	strength,	the	following	ehanced	chemoluminescence	(ECL)	reagents	were	
utilised	depending	on	the	concentration	of	protein	present	in	the	membrane:	Luminata	Classico	
Western	horseradish	peroxidase	(HRP)	substrate	(Millipore),	Luminata	Crescendo	Western	HRP	
substrate	(Millipore),	SuperSignalTM	West	Femto	Maximum	Sensitivity	Substrate	(Fisher	Scientific).	
Membranes	were	incubated	with	1ml	of	reagent	for	1	minute	at	room	temperature,	before	being	
transferred	to	saran	wrap	in	a	developing	cassette	(Amersham)	which	was	sealed	to	avoid	bubbles.	
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Proteins	were	visualised	by	exposing	membranes	to	radiographic	film	(Kodak)	for	15	seconds	to	5	
minutes,	and	then	processing	in	a	mini	developer	(Konica	SRX-101A	medical	film	processor).		
	
4.7.6 Stripping	and	re-probing	of	PVDF	membranes	
	
Membranes	were	incubated	with	RestoreTM	PLUS	Western	Blot	Stripping	Buffer	(Fisher	Scientific)	
according	to	manufacturer’s	instructions,	allowing	the	membrane	to	be	re-probed	with	a	different	
antibody	as	described.	
	
4.7.7 Quantification	of	immunoblots	
	
Films	were	scanned	at	600dpi	and	saved	as	TIFF	files.	The	images	were	analysed	in	ImageJ	software	
(NIH)	by	scanning	densitometry.	Bands	were	manually	outlined	using	the	rectangular	shape	selection	
tool	and	the	pixel	intensity	measured	as	the	area	under	the	peak.		
Data	was	processed	in	Microsoft	Excel	and	normalised	as	appropriate.	Values	were	exported	to	
GraphPad	Prism	for	statistical	analysis.		
	
4.8 PROTEIN	BIOCHEMISTRY	METHODS	
	
4.8.1 J20	mice	
	
At	16-18	months	of	age,	J20	mice	were	sacrificed	under	Schedule	1	of	the	Home	Office	Animal	
Welfare	Regulations.	Cortices,	hippocampi	and	cerebella	were	dissected	and	snap-frozen	on	dry	ice.	
They	were	then	stored	at	-80°C	until	homogenised.	
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4.8.2 Brain	homogenisation	
	
All	utensils	and	a	pestle	and	mortar	were	pre-chilled	on	dry	ice.	Frozen	brain	tissue	was	cut	into	
small	pieces	with	a	scalpel,	transferred	into	a	pestle	and	mortar	and	covered	in	liquid	nitrogen.	The	
liquid	nitrogen	was	left	to	evaporate	and	then	the	tissue	ground	into	a	fine	powder.	A	chilled	spatula	
was	used	to	transfer	the	powder	into	an	eppendorf,	and	the	eppendorf	stored	in	an	urn	of	liquid	
nitrogen.	This	was	repeated	for	all	samples.	250μl	of	chilled	homogenisation	buffer	was	then	added	
to	each	sample	before	placing	on	ice.	Tissue	was	sonicated	on	ice	and	then	centrifuged	for	20	
minutes	at	16,000	xg	and	4°C.	A	Bradford	assay	was	carried	out	on	the	supernatant	to	determine	
protein	concentrations.		
	
4.8.3 Bradford	assay	
	
Protein	concentration	was	determined	following	a	modified	version	of	the	Bradford	method	
(Bradford,	1976)	and	using	BioRad	reagent.	BSA	standard	curves	were	created	with	serial	dilutions	
from	0.1mg/ml	to	2mg/ml.	BioRad	reagent	was	diluted	1	in	5	with	ddH20	and	995μl	was	added	to	5μl	
of	each	sample	in	a	1ml	cuvette.	A	spectrophotometer	was	normalised	to	the	homogenisation	buffer	
and	optical	density	measured	at	a	wavelength	of	595nm.	A	total	of	3	readings	were	taken	per	
sample,	averaged	and	then	plotted	against	the	BSA	standard	curve.	Protein	concentrations	were	
extrapolated	accordingly.		
	
4.9 IMMUNOCYTOCHEMISTRY	
4.9.1 Total	immunocytochemistry	
	
For	total	staining,	DIV15	hippocampal	neurons	were	fixed	in	4%	paraformaldehyde	(PFA)/4%	
sucrose/1x	Dulbecco’s	(D)PBS	for	15	minutes,	washed	3	times	in	1xDPBS,	quenched	in	0.1M	
glycine/1xDPBS	for	5	minutes	and	then	washed	another	3	times	in	1xDPBS.	Permeabilisation	in	0.1%	
Triton	X-100/5%BSA/1xDPBS	for	10	minutes	followed.	Coverslips	were	then	incubated	in	primary	
antibody	diluted	in	5%BSA/1xDPBS	for	1	hour,	washed	3	times	in	1xDBPS	and	incubated	with	
AlexaFluor488	secondary	antibody	diluted	in	5%BSA/1xDPBS	for	45	minutes.	Coverslips	were	
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washed	5	times	in	1xDPBS	before	being	mounted	onto	glass	slides	using	Fluoromount	G	(Fisher	
Scientific).		
	
4.9.2 Antibody	feeding	assay	
	
For	live	surface	staining,	coverslips	were	incubated	with	HBS	pre-warmed	to	37°C	for	6	minutes	
before	being	incubated	in	primary	antibody	diluted	in	HBS	for	20	minutes.	Coverslips	were	washed	in	
HBS	and	returned	to	conditioned	media	for	either	20	or	45	minutes	at	37°C	(figure	4-2).	Neurons	
were	fixed	with	4%PFA/4%sucrose/1xDPBS	for	5	minutes,	washed	3	times	in	1xDPBS,	quenched	in	
0.1M	glycine/1xDPBS	and	washed	another	3	times	in	1xDPBS.	Coverslips	were	then	incubated	with	
AlexaFluor488	secondary	antibody	diluted	in	5%BSA/1xDPBS,	washed	5	times	in	1xDPBS	and	fixed	
again	in	4%PFA/4%sucrose/1xDPBS	for	12	minutes.	Neurons	were	permeabilised	for	10	minutes	in	
0.1%	Triton	X-100/5%BSA/1xDPBS	and	then	incubated	with	lysosomal-associated	membrane	protein	
1	(LAMP1)	primary	antibody	diluted	in	5%BSA/1xDPBS	for	1	hour.	3	washes	in	1xDPBS	followed	and	
incubation	with	AlexaFluor647	and	Dylight405	for	45	minutes.	Coverslips	were	then	washed	and	
mounted	as	described	in	section	4.8.1.		
In	order	to	block	lysosomal	degradation,	100 μg/ml	leupeptin	was	added	to	the	culture	medium	for	
3 hours	before	and	during	primary	antibody	incubation	and	trafficking.	
	
Figure	4-2	Timeline	of	major	steps	in	antibody	feeding	immunocytochemistry	protocol.	
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4.9.3 Image	acquisition	and	analysis	
	
Images	were	acquired	on	an	SP5-AOBS	(Leica)	confocal	laser	scanning	microscope	attached	to	a	DM	
I6000	(Leica)	inverted	epifluorescence	microscope	using	a	40x	or	63x	oil	immersion	objective	lens.	
For	total	immunocytochemistry,	the	Leica	application	suite	software	was	used	to	acquire	0.5-μm	
stepped	Z-stacks	throughout	the	cell	depth	and	maximum	projections	were	taken	for	each	series.	
Images	were	obtained	with	a	resolution	of	1024x1024	pixels	at	1x	optical	zoom,	a	pinhole	of	1	airy	
unit	(AU)	at	400Hz	averaged	6	times.	Acquisition	parameters	were	kept	constant	across	all	coverslips	
per	experiment.	Images	were	analysed	using	ImageJ	software.	
4.10 STATISTICAL	ANALYSIS	
	
Data	are	presented	as	mean	±	standard	error	of	the	mean	(SEM).	Mean	gray	values	normalised	to	
the	MV	control	conditions	separately	for	each	dissection	which	accounted	for	differences	between	
experiments	carried	out	on	neuronal	cultures	from	different	dissections.		
For	total	immunocytochemistry,	the	n	value	given	for	each	experiment	refers	to	the	number	of	
coverslips	(taken	from	different	dissections)	and	each	data	point	is	an	average	of	3	cells.	Average	
mean	gray	value	was	measured	for	each	cell	and	processed	for	statistical	evaluation.		
For	antibody	feeding	assays,	three	30-40μM	portions	of	distal	dendrites	were	analysed	per	cell.	The	
n	value	refers	to	the	number	of	coverslips	(taken	from	different	dissections)	with	each	coverslip	
averaged	from	three	cells	with	three	~30-40μm	portions	of	dendrite	per	cell.	Pearson’s	co-
localisation	analysis	was	performed	using	the	Coloc	2	plugin	in	ImageJ.	
For	western	blotting	experiments	on	J20	mice,	the	n	value	refers	to	the	number	of	brain	
homogenisation	preparations,	with	each	preparation	containing	five	WT	and	six	J20	mice.	For	
western	blotting	experiments	on	cortical	neuronal	cultures,	the	n	values	refer	to	the	number	of	
cortical	cultures.	
Data	were	first	tested	for	normality	using	the	Shapiro-Wilk	normality	test	to	determine	the	
appropriate	statistical	test.	If	found	to	fit	a	normal	distribution,	data	were	analysed	using	parametric	
statistics.	Two-tailed	Student’s	t-tests	were	used	for	comparing	2	groups	of	data	and	a	one-way	
analysis	of	variance	(ANOVA)	used	when	3	or	more	groups	were	compared.	A	Bonferroni’s	post-hoc	
test	for	multiple	comparisons	was	used	to	compare	all	variables	with	one	another.		
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Data	sets	exhibiting	non-normal	distributions	were	analysed	with	non-parametric	statistical	tests.	
Experiments	with	2	variables	were	analysed	with	Mann	Whitney	tests	for	unpaired	data	and	
Wilcoxon	matched-pairs	signed	rank	tests	for	paired	data.	Experiments	with	more	than	2	variables	
were	analysed	with	Kruskal-Wallis	one-way	ANOVAs.	All	statistical	tests	were	performed	on	
GraphPad	Prism	(v8.0).	Differences	were	considered	significant	if	*	p	<	0.05,	**p	<	0.01,	***p	<	
0.001,	****p	<	0.0001.		
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5 GLUA1	AND	GLUA2	DEGRADATION	IN	ALZHEIMER’S	DISEASE	MODELS	
5.1 AIMS	
	
The	first	aims	of	my	project	were	to	investigate	the	total	expression	levels	of	the	AMPAR	subunits	
GluA1	and	GluA2,	which	can	indicate	whether	a	change	in	subunit	degradation	is	witnessed	in	the	
disease	state	in	vitro.	Subunit	expression	was	examined	in	three	separate	models	of	AD	to	determine	
similarities	and	distinctions	that	might	arise	between	different	models	mimicking	distinct	
pathological	characteristics	of	the	disease.	It	was	hypothesised	that	expression	levels	of	GluA1	and	
GluA2	would	be	reduced	in	all	three	models	due	to	their	degradation	in	response	to	amyloidopathy.	
	
5.2 INTRODUCTION	
	
Although	both	tau	and	Aβ	are	key	to	the	pathogenesis	of	AD,	strong	evidence	from	genetics	and	
transgenic	mice	has	implicated	Aβ	to	be	strongly	associated	with	disruption	of	synaptic	function	
(Guntupalli,	Widagdo	and	Anggono,	2016).	Furthermore,	the	genes	firmly	indicated	in	the	
pathophysiology	of	familial	AD	all	result	in	Aβ	pathogenesis,	allowing	this	hallmark	of	the	disease	to	
be	modelled	(Reitz,	Brayne	and	Mayeux,	2011).	Thus,	the	most	commonly	used	experimental	models	
of	AD	in	vivo	are	transgenic	mice	that	overexpress	human	genes	associated	with	familial	AD	and	
mimic	the	formation	of	Aβ	plaques	(Drummond	and	Wisniewski,	2017).	It	was	discovered	that	
mouse	strains	expressing	numerous	familial	AD	mutations	at	once	exhibit	more	severe	pathology	
(Mucke	et	al.,	2000).	As	a	result,	models	such	as	the	J20	mouse	strain	were	developed,	which	
expresses	both	the	Swedish	(APPK670N/M671L)	and	Indiana	(APPV717F)	mutations	(Mucke	et	al.,	2000)	and	
exhibits	a	host	of	AD	phenotypes	comprising	deficits	in	both	LTP	(Saganich	et	al.,	2006)	and	cognition	
(Cheng	et	al.,	2007;	Wright	et	al.,	2013).		
Modelling	amyloidopathy	in	vitro	is	often	afforded	by	neuronal	cell	cultures	which	provide	an	easily	
manipulated	and	controlled	environment	for	revealing	molecular	and	cellular	mechanisms	of	disease	
states	(Akhter,	Sanphui	and	Biswas,	2014).	There	are	a	number	of	techniques	that	can	be	
implemented	to	replicate	the	actions	of	Aβ	in	culture,	including	APP	overexpression.	This	approach	
has	previously	been	validated	and	demonstrated	to	result	in	AD	pathology	such	as	a	loss	of	spine	and	
dendritic	AMPAR	subunits	(Kamenetz	et	al.,	2003;	Hsieh	et	al.,	2006).	A	better	technique	to	mimic	
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the	pathological	hallmarks	of	amyloidopathy	in	culture	would	be	the	endogenous	expression	of	APP	
with	human	mutations.	This	would	be	advantageous	because	not	only	would	it	allow	APP	with	
clinically	relevant	familial	mutations	to	be	expressed,	but	they	would	be	expressed	at	endogenous	
levels	which	avoids	any	artefacts	that	might	result	from	protein	overexpression	(Kuang	et	al.,	2006).		
Since	AMPARs	mediate	the	overwhelming	majority	of	fast	excitatory	transmission	in	the	central	
nervous	system,	changes	to	their	composition	and	properties	at	the	post-synaptic	membrane	
significantly	modify	synaptic	function	and	neuronal	connectivity.	Indeed,	the	synaptic	dysfunction	
that	is	a	characteristic	of	AD	can	be	explained	by	a	loss	of	the	AMPAR	subunits	GluA1	and	GluA2	
from	the	synaptic	surface	(Hsieh	et	al.,	2006;	Liu	et	al.,	2010;	Zhao	et	al.,	2010;	Miñano-Molina	et	al.,	
2011;	Alfonso	et	al.,	2014).	Aβ	facilitates	the	loss	of	surface	AMPAR	levels	via	a	range	of	mechanisms	
including:	the	activation	of	calcineurin	and	subsequent	dephosphorylation	of	AMPARs	at	Ser-845	
(Zhao	et	al.,	2009;	Miñano-Molina	et	al.,	2011);	the	phosphorylation	of	AMPARs	at	Ser-880	and	
subsequent	dissociation	from	GRIP	(Liu	et	al.,	2010);	the	increased	association	of	AMPARs	with	PICK1	
(Alfonso	et	al.,	2014);	altered	localisation	of	CaMKII	at	the	synapse	(Gu,	Liu	and	Yan,	2008);	and	
reduced	synaptic	expression	of	PSD-95	(Gylys	et	al.,	2004;	Almeida	et	al.,	2005;	Proctor,	Coulson	and	
Dodd,	2010;	Sultana,	Banks	and	Butterfield;	2010).	Although	some	of	these	mechanisms	suggest	that	
receptors	are	lost	from	the	surface	via	an	increase	in	AMPAR	endocytosis,	another	mechanism	that	
could	be	responsible	for	receptor	loss	from	the	surface	is	a	disruption	to	their	recycling.	Indeed,	
instead	of	being	trafficked	to	recycling	endosomes	(REs),	receptors	can	be	targeted	to	late	
endosomes	(LEs)	where	they	are	subsequently	degraded	(van	der	Sluijs	and	Hoogenraad,	2011;	Hu	et	
al.,	2015).	If	this	were	happening,	a	loss	of	total	AMPAR	expression	would	be	expected.	
The	levels	of	GluA1	and	GluA2	protein	expression	have	been	examined	in	AD	brain	tissue.	Indeed,	
immunocytochemical	and	biochemical	techniques	reveal	that	both	GluA1	(Armstrong	et	al.,	1994;	
Yasuda	et	al.,	1995)	and	GluA2	(Armstrong	et	al.,	1994;	Yasuda	et	al.,	1995;	Ikonomovic	et	al.,	1997;	
Carter	et	al.,	2004)	protein	levels	are	reduced,	particularly	in	the	entorhinal	cortex	and	subiculum	of	
AD	post-mortem	brains.	Although	not	all	of	the	literature	demonstrates	this	reduction,	this	conflict	
occurs	in	studies	where	messenger	(m)RNA	rather	than	protein	levels	were	being	examined	
(Pellegrini-Giampietro,	Bennett	and	Zukin,	1994).	Since	a	change	to	protein	expression	can	indicate	
transcriptional	down-regulation	of	protein	messenger	(m)RNA	or	changes	in	protein	degradation	
(Goo,	Scudder	and	Patrick,	2015),	this	suggests	that	these	subunits	are	being	degraded	rather	than	
any	change	to	transcriptional	control.	On	balance	the	evidence	suggests	that	these	AMPAR	subunits	
are	vulnerable	to	down-regulation	in	the	disease	state.	
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Based	on	the	observation	that	synapses	get	weaker	in	AD	rodent	models	(Cullen	et	al.,	1997;	Walsh	
et	al.,	2002;	Wang	et	al.,	2002;	Shanker	et	al.,	2007,	Shanker	et	al.,	2008)	AMPARs	are	lost	from	
synapses	in	vitro	(Hsieh	et	al.,	2006;	Liu	et	al.,	2010;	Zhao	et	al.,	2010;	Miñano-Molina	et	al.,	2011;	
Alfonso	et	al.,	2014),	and	AMPARs	are,	generally	speaking,	reduced	in	post-mortem	AD	brains	
compared	to	controls	(Armstrong	et	al.,	1994;	Yasuda	et	al.,	1995;	Ikonomovic	et	al.,	1997;	Carter	et	
al.,	2004),	it	was	hypothesised	that	AMPARs	may	be	degraded	in	response	to	amyloidopathy	and	
thus	their	expression	would	be	reduced.	
This	chapter	examined	the	expression	of	AMPAR	subunits	in	three	different	models	of	
amyloidopathy.	Since	GluA1	and	GluA2	predominate	in	the	mature	hippocampus,	it	was	decided	to	
focus	on	the	total	expression	of	these	subunits	(Wenthold	et	al.,	1996;	Lu	et	al.,	2009).	The	three	
models	that	were	investigated	each	mimicked	Aβ	pathogenesis	in	different	ways:	the	overexpression	
of	APPWT	in	culture,	the	expression	of	a	familial	APP	mutation	at	endogenous	levels	in	culture,	and	a	
transgenic	mouse	strain	carrying	two	familial	APP	mutations.			
	
5.3 RESULTS	
	
5.3.1 Overexpression	of	APPWT	causes	a	loss	of	total	GluA2	
	
The	first	model	of	amyloidopathy	used	to	look	at	GluA1	and	GluA2	degradation	was	the	transfection	
of	hippocampal	neuronal	cultures	with	APPWT	or	APPMV.	It	has	previously	been	demonstrated	that	
the	overexpression	of	APPWT	results	in	greater	production	of	Aβ,	leading	to	AD	phenotypes	including	
synaptic	removal	of	AMPARs,	dendritic	spine	loss	and	the	occlusion	of	LTD	(Kamenetz	et	al.,	2003;	
Hsieh	et	al.,	2006).	APPMV	is	a	point	mutant	of	APP	with	a	M596V	mutation	(Citron,	Teplow	and	
Selkoe,	1995)	and	can	be	used	as	a	suitable	control	construct	since	it	can	only	be	cleaved	by	α-
secretase	and	not	β-secretase	(Kamenetz	et	al.,	2003).	Thus,	differences	between	APPWT	and	APPMV	
expressing	cells	are	caused	by	BACE	activity	and	Aβ	generation.	Indeed,	APPMV	had	no	effect	on	
glutamatergic	synaptic	transmission,	while	APPWT	overexpression	depressed	transmission	which	was	
attributable	to	Aβ	production	(Kamenetz	et	al.,	2003).	Differences	in	GluA1	or	GluA2	expression	
levels	observed	between	the	effects	of	overexpressing	APPWT	or	APPMV	should	therefore	be	
attributable	to	increased	levels	of	Aβ.		
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Changes	to	total	AMPAR	expression,	as	well	as	a	change	to	transcriptional	control,	can	indicate	a	
change	in	degradation	and	can	be	visualised	by	labelling	subunits	under	permeabilising	conditions	to	
measure	both	surface	and	internalised	receptors.	Experiments	were	carried	out	in	DIV15	
hippocampal	neuronal	cultures	transfected	with	APPWT	or	APPMV	for	48	hours.	Immunocytochemistry	
was	then	carried	out	whereby	neurons	were	fixed	and	permeabilised	before	total	staining	for	GluA1	
and	GluA2	to	investigate	if	Aβ	production	affected	total	GluA2	or	GluA1	expression.		
	
Figure	5-1	Overexpression	of	APPWT	in	hippocampal	neuronal	cultures	reduces	total	GluA2	expression.		
(A) DIV13	primary	hippocampal	neurons	were	transfected	with	plasmids	encoding	APPWT-IRES-mCherry	or	APPMV-
IRES-mCherry	and	returned	to	conditioned	media	for	48	hours.	Cells	were	then	fixed	at	DIV15,	permeabilised	and	
labelled	for	total	GluA2.	Transfected	cells	were	identified	by	mCherry	fluorescence	(red	channel).	The	green	
channel	represents	staining	for	total	GluA2.	Scale	bar=30μm.	
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(B) Quantification	of	mean	fluorescence	intensity	of	total	GluA2	in	transfected	neurons.	n=5.	Paired	two-tailed	
student’s	t-test,	*p=0.0365.		
	
	
	
Figure	5-2	Overexpression	of	APPWT	in	hippocampal	neuronal	cultures	does	not	alter	total	GluA1	expression.	
(A) DIV13	primary	hippocampal	neurons	were	transfected	with	plasmids	encoding	APPWT-IRES-mCherry	or	APPMV-
IRES-mCherry	and	returned	to	conditioned	media	for	48	hours.	Cells	were	then	fixed	at	DIV15,	permeabilised	and	
labelled	for	total	GluA1.	Transfected	cells	were	identified	by	mCherry	fluorescence	(red	channel).	The	green	
channel	represents	staining	for	total	GluA1.	Scale	bar=30μm.	
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(B) Quantification	of	mean	fluorescence	intensity	of	total	GluA1	in	transfected	neurons.	n=5.	Paired	two-tailed	
student’s	t-test,	p=0.2241.		
	
Figure	5-1	showed	that	APPWT	overexpression	decreased	total	GluA2	expression	compared	to	APPMV	
control	cells.	In	contrast,	figure	5-2	demonstrated	that	GluA1	expression	levels	were	not	affected	by	
APPWT	overexpression,	since	there	was	no	significant	difference	compared	to	APPMV	cells.	Therefore,	
only	total	GluA2	levels	were	shown	to	decrease	in	response	to	APPWT	overexpression,	indicating	that	
elevated	Aβ	might	be	causing	the	selective	entry	of	GluA2-containing	AMPARs	into	a	degradative	
path.	Figure	5-1	A	demonstrates	that	all	neurons	in	the	field	of	view	transfected	with	APPWT	have	
reduced	GluA2	expression	levels	compared	to	control	neurons,	which	suggests	Aβ	secreted	from	the	
transfected	neuron	could	be	affecting	expression	in	neighbouring	cells.	
	
5.3.2 Validation	of	APP	molecular	replacement	lentiviral	constructs		
	
The	second	AD	model	used	to	look	at	GluA1	and	GluA2	degradation	was	the	infection	of	cortical	
neuronal	cultures	with	APPSWE	and	APPWT	knockdown-replacement	viruses.	This	was	a	technique	
developed	by	our	lab	to	replace	endogenous	APP	with	a	clinically	relevant	familial	mutation	in	
culture.	Whilst	APPSWE	had	already	been	developed,	during	the	project	we	cloned	an	APPWT	control	
which	allowed	these	viruses	to	be	used	for	the	first	time	to	explore	the	molecular	mechanisms	of	the	
disease.	Viral	delivery	of	shRNAs	provides	an	efficient	means	to	suppress	endogenous	or	
heterologous	gene	expression	in	cultured	cells	without	the	complications	related	to	genetic	ablation	
of	a	protein	(Fellmann	and	Lowe,	2014).	Furthermore,	this	technique	was	superior	to	the	previous	
model	because	it	allowed	the	expression	of	clinically	relevant	mutations	in	culture	and	avoided	any	
artefacts	that	might	result	from	protein	overexpression.		
It	was	first	necessary	to	validate	whether	the	molecular	replacement	constructs	could	knockdown	
endogenous	APP	and	replace	it	with	an	appropriate	level	of	APPWT	or	APPSWE	in	cortical	neurons.	
Cortical	neurons	were	used	in	this	case	instead	of	hippocampal	due	to	time	constraints	so	that	a	high	
density	of	neurons	could	be	plated	for	Western	blots.	Cortical	neuronal	cultures	were	transduced	
with:	the	scrambled	shRNA	(Scr)	with	an	enhanced	green	fluorescent	protein	(EGFP)	reporter;	APP	
shRNA	(Sh-APP)	with	a	GFP	reporter;	the	APPWT	knockdown	replacement	construct	(Shres-APPWT)	
which	expresses	APP	shRNA	as	well	as	human	APP	with	a	C-terminal	myc	tag;	or	the	APPSWE	
knockdown	replacement	construct	(Shres-APPSWE)	which	also	expresses	APP	shRNA	as	well	as	human	
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APP	with	a	C-terminal	myc	tag.	Cells	were	then	lysed	4	days	later	and	samples	immunoblotted	for	
APP,	myc	and	β-tubulin.		
	
Figure	5-3	Validation	of	APP	knockdown	and	replacement	with	myc-tagged	APPWT	and	APPSWE.	
(A) DIV12-16	cortical	neurons	were	transduced	with	lentiviral	molecular	replacement	constructs	and	returned	to	
conditioned	media	for	4	days.	Cells	were	then	lysed	and	immunoblotted	for	APP	and	β-tubulin.		
(B) Quantification	of	APP	protein	levels	was	calculated	by	normalising	APP	to	β-tubulin	values,	which	were	obtained	
through	quantitative	densitometry.	n=5.	One-way	ANOVA	with	Bonferroni’s	test	for	multiple	comparisons,	
***p=0.0001,	****p<0.0001.		
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(C) DIV12-16	cortical	neurons	were	transduced	with	lentivirus	molecular	replacement	constructs	and	returned	to	
conditioned	media	for	4	days.	Cells	were	then	lysed	and	immunoblotted	for	myc	and	β-tubulin.	
(D) Quantification	of	myc	protein	levels	was	calculated	by	normalising	myc	to	β-tubulin	values,	which	were	obtained	
through	quantitative	densitometry.	n=1.	
(E) Samples	were	run	on	8%	gel	to	demonstrate	the	difference	in	molecular	weight	between	endogenous	and	
recombinant	protein,	caused	by	the	presence	of	the	myc	tag.	
Figure	5-3	B	demonstrated	that	cells	expressing	APP	shRNA	showed	a	dramatic	reduction	in	
endogenous	APP	expression.	Both	Shres-APPWT	and	Shres-APPSWE	rescued	APP	protein	expression	to	
endogenous	levels	since	APP	densitometry	was	not	significantly	different	from	Scr	control	levels.	
Myc	bands	confirmed	the	replacement	of	endogenous	APP	with	myc-tagged	APPWT	or	APPSWE	(figure	
5-3	D).	Figure	5-3	E	demonstrates	that	when	samples	were	run	on	8%	gel	there	was	a	difference	in	
molecular	weight	between	endogenous	and	recombinant	protein,	providing	an	additional	validation	
that	endogenous	APP	was	being	knocked	down	and	replaced	with	myc-tagged	APPWT	or	APPSWE.	
	
5.3.3 Replacing	endogenous	APP	with	APPSWE	causes	a	loss	of	total	GluA2	
	
The	Tg2576	mouse	expressing	human	APP	with	the	double	Swedish	mutation	(APPK670N/M671L)	has	
previously	demonstrated	deficits	in	LTP	(Fryer	et	al.,	2003),	a	loss	of	dendritic	spine	density	(Lanz,	
Carter	and	Merchant,	2003)	and	cognitive	impairments	(Jacobsen	et	al.,	2006).	These	deficits	can	be	
indicative	of	aberrant	AMPAR	recycling.	Together	with	the	evidence	that	synaptic	weakening	occurs	
in	AD	(Cullen	et	al.,	1997;	Walsh	et	al.,	2002;	Wang	et	al.,	2002;	Shanker	et	al.,	2007,	Shanker	et	al.,	
2008)	and	that	LTD	is	facilitated	in	response	to	amyloidopathy	(Shanker	et	al.,	2008;	Li	et	al.,	2009),	
studying	AMPAR	degradation	in	a	cell	culture	model	expressing	APPSWE	would	be	of	interest	since	
changes	to	their	composition	and	properties	at	the	post-synaptic	membrane	can	significantly	modify	
synaptic	function	and	neuronal	connectivity.	Cortical	neuronal	cultures	were	infected	with	the	
molecular	replacement	constructs	as	before	and	lysed	4	days	later	before	immunoblotting	for	GluA1	
or	GluA2.	
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Figure	5-4	Knockdown	of	endogenous	APP	and	replacement	with	APPSWE		in	cortical	neuronal	cultures	reduces	total	GluA2	
expression.	
DIV12-16	cortical	neurons	were	transduced	with	lentiviral	molecular	replacement	constructs	and	returned	to	
conditioned	media	for	4	days.	Cells	were	then	lysed	and	immunoblotted	using	the	indicated	antibodies.	
(A) Representative	Western	blots	of	GluA2	and	β-tubulin.		
(B) Quantification	of	GluA2	protein	levels	was	calculated	by	normalising	GluA2	to	β-tubulin	values,	which	were	
obtained	through	quantitative	densitometry.	n=10-12.	One-way	ANOVA	with	Bonferroni’s	test	for	multiple	
comparisons,	*p=0.0407.		
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(C) Representative	Western	blots	of	GluA1	and	β-tubulin.		
(D) Quantification	of	GluA1	protein	levels	was	calculated	by	normalising	GluA1	to	β-tubulin	values,	which	were	
obtained	through	quantitative	densitometry.	n=10.	One-way	ANOVA	with	Bonferroni’s	test	for	multiple	
comparisons,	p=0.7439.		
Figure	5-4	B	showed	that	knockdown	of	endogenous	APP	and	replacement	with	APPSWE	decreased	
total	GluA2	expression	compared	to	APPWT	control	cells.	In	contrast,	figure	5-4	D	demonstrated	that	
GluA1	expression	levels	were	not	regulated	by	APPSWE	expression,	since	no	significant	difference	was	
witnessed	compared	to	APPWT	expression.	Therefore,	only	total	GluA2	levels	were	decreased	in	
response	to	the	APP	Swedish	mutant.		
	
5.3.4 Validation	of	APP	overexpression	in	J20	mouse	models	
	
The	third	AD	model	used	to	look	at	GluA1	and	GluA2	expression	was	the	J20	mouse	model.	J20	mice	
overexpress	APP	with	both	the	Swedish	(APPK670N/M671L)	and	Indiana	(APPV717F)	mutations.	These	mice	
should	therefore	demonstrate	APP	overexpression	compared	to	controls,	with	the	APP	mutations	
responsible	for	the	AD	phenotypes.	At	16-18	months	of	age,	six	J20	mouse	brains	and	five	WT	mouse	
brains	were	snap	frozen	on	dry	ice	and	stored	at	-80°C	before	homogenisation	and	immunoblotting	
for	GluA1	and	GluA2.		
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Figure	5-5	J20	mouse	models	overexpress	APP.	
(A) Five	16-18	month-old	WT	mouse	brain	and	six	16-18	month	old	J20	mouse	brains	were	homogenised	and	7.5ug	
separated	by	SDS-PAGE	and	immunoblotted	using	the	indicated	antibodies.	
(B) Quantification	of	APP	protein	levels	was	calculated	by	normalising	GluA2	to	β-tubulin	values,	which	were	
obtained	through	quantitative	densitometry.	n=10-12.	Mann	Whitney	test,	****p<0.0001.		
Figure	5-5	B	demonstrated	that	APP	was	significantly	overexpressed	in	J20	mouse	brain	compared	to	
WT	controls.	
	
5.3.5 J20	mouse	models	demonstrate	no	change	in	GluA1	or	GluA2	expression	
	
The	J20	mouse	model	has	demonstrated	deficits	in	LTP	(Saganich	et	al.,	2006)	and	cognitive	
impairments	on	the	Morris	water	maze	(Cheng	et	al.,	2007)	and	radial	arm	maze	(Wright	et	al.,	
2013).	Furthermore,	depletions	in	the	expression	of	GluA1	and	GluA2	have	been	observed	in	the	
dentate	gyrus	of	J20	mice	(Palop	et	al.,	2007).	We	investigated	whether	or	not	a	loss	of	GluA1	or	
GluA2	expression	occurred	in	the	cortex	of	J20	mouse	brain.	WT	and	J20	mouse	brain	were	
homogenised	as	before	and	immunoblotted	for	GluA1	or	GluA2.	
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Figure	5-6	GluA1	and	GluA2	subunit	expression	levels	are	not	affected	in	J20	mouse	models.	
Five	16-18	month	old	WT	mouse	brain	and	six	16-18	month	J20	mouse	brains	were	homogenised	and	7.5ug	separated	by	
SDS-PAGE	and	immunoblotted	using	the	indicated	antibodies.	
(A) Representative	Western	blots	of	GluA2	and	β-tubulin.		
(B) Quantification	of	GluA2	protein	levels	was	calculated	by	normalising	GluA2	to	β-tubulin	values,	which	were	
obtained	through	quantitative	densitometry.	n=3.	Paired	two-tailed	student’s	t-test,	p=0.3884.		
(C) Representative	Western	blots	of	GluA1	and	β-tubulin.		
(D) Quantification	of	GluA1	protein	levels	was	calculated	by	normalising	GluA2	to	β-tubulin	values,	which	were	
obtained	through	quantitative	densitometry.	n=3.	Paired	two-tailed	student’s	t-test,	p=0.7763.		
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Figure	5-6	B	demonstrated	that	there	was	no	significant	change	in	GluA2	expression	levels	between	
J20	mouse	models	and	WT	controls.	There	was	also	no	significant	difference	in	GluA1	expression	
(figure	5-6	D).	These	results	were	surprising	given	the	results	from	our	other	two	models	and	from	
previous	J20	mouse	studies	(Palop	et	al.,	2007).		
	
5.4 DISCUSSION	
	
5.4.1 Reduced	GluA2	expression	following	APPWT	overexpression	and	APPSWE	expression	
	
Figure	5-1	B	demonstrated	that	a	decrease	in	total	GluA2	expression	was	observed	in	response	to	
APPWT	overexpression.	This	could	not	be	seen	with	total	GluA1	expression	levels	(figure	5-2	B).	
Similarly,	figure	5-4	B	demonstrated	that	total	GluA2	expression	was	reduced	in	response	to	APPSWE	
expression,	but	GluA1	expression	was	not	affected	(figure	5-4	D).	Although	a	change	to	protein	
expression	can	indicate	transcriptional	down-regulation	of	protein	messenger	(m)RNA,	it	can	also	
suggest	changes	in	protein	degradation	(Goo,	Scudder	and	Patrick,	2015).	Given	it	has	previously	
been	demonstrated	in	the	literature	that	both	GluA1	and	GluA2	are	reduced	in	post-mortem	AD	
brains	compared	to	controls	(Yasuda	et	al.,	1995;	Carter	et	al.,	2004;	Palop	et	al.,	2007;	Resende	et	
al.,	2007)	it’s	possible	that	amyloidopathy	could	trigger	the	selective	degradation	of	GluA2-
containing	AMPARs.	However,	neuronal	protein	degradation	pathways	need	to	be	examined	before	
conclusions	can	be	drawn	on	this.	
The	observation	that	GluA2	but	not	GluA1	receptor	subunits	exhibited	reduced	expression	in	both	of	
the	above	models	demonstrates	that	the	disease	phenotype	did	not	result	in	the	non-specific	loss	of	
all	surface	proteins	and	indicates	that	Aβ	acts	through	a	selective	mechanism	that	is	AMPAR	subunit	
specific.	It	might	be	that	these	models	of	amyloidopathy	do	not	capture	the	mechanisms	responsible	
for	GluA1	subunit	changes	in	human	post-mortem	tissues.	Indeed,	it	has	been	suggested	that	tau	
phosphorylation	is	required	to	act	as	an	intermediate	signalling	molecule	between	Aβ	initiation	and	
eventual	synaptic	dysfunction,	since	Aβ-induced	synaptic	impairments	are	diminished	by	the	
expression	of	a	tau	construct	that	cannot	be	phosphorylated	(Miller	et	al.,	2014).	
However,	differential	effects	on	AMPAR-subunits	are	not	unusual	and	have	been	witnessed	in	other	
disease	states	including	ischaemic	brain	injury	(Dixon,	Mellor	and	Hanley,	2009;	Blanco-Suarez	and	
Hanley,	2014)	and	amyotrophic	lateral	sclerosis	(Kawahara	et	al.,	2004;	Kwak	et	al.,	2010).	Given	that	
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the	majority	of	AMPARs	in	the	mature	hippocampus	are	made	up	of	GluA1/2	or	GluA2/3	heteromers	
(Wenthold	et	al.,	1996;	Lu	et	al.,	2009),	the	results	indicate	that	GluA2/3	receptors	could	be	
vulnerable	to	the	effects	of	Aβ	whilst	GluA1/2	heteromers	are	protected	by	an	unknown	mechanism.	
A	more	recent	study	showing	that	the	GluA3	subunit	is	important	in	the	response	to	Aβ	provides	
further	support	to	this	idea	(Reinders	et	al.,	2016).	
A	similar	model	for	the	specific	loss	of	GluA2/3	heteromers	has	been	proposed	in	response	to	
ischaemia	(Koszegi	et	al.,	2017)	however	here,	GluA2	down-regulation	was	observed	in	hippocampal	
but	not	cortical	neurons	and	was	thus	dependent	on	a	cell-type	specific	mechanism	involving	PICK1.	
In	our	experiments,	a	loss	of	GluA2	expression	was	demonstrated	in	both	cortical	and	hippocampal	
in	vitro	models	of	AD,	indicating	the	involvement	of	molecular	cell	biology	that	is	common	to	both	
cell	types.		
	
5.4.2 APPWT	overexpression	and	AMPARs	
	
In	the	past	researchers	have	struggled	to	generate	models	of	AD	that	overproduce	Aβ	without	
overexpressing	APP,	therefore	in	order	to	mimic	Aβ	pathology	many	research	groups	have	utilised	
models	that	overexpress	human	WT	APP	(Kamenetz	et	al.,	2003;	Hsieh	et	al.,	2006;	Simón	et	al.,	
2009)	or	APP	with	human	mutations	(Gu,	Liu	and	Yan,	2008;	Cantanelli	et	al.,	2014).	However,	
increasing	gene	expression	beyond	physiological	levels	can	introduce	artefacts	including	the	
interference	of	protein	homeostasis,	which	triggers	apoptosis	(Kuang	et	al.,	2006).	Thus,	some	
researchers	believe	that	APP	overexpression	is	an	artificial	means	to	model	AD.	Indeed,	it	has	been	
demonstrated	that	some	phenotypes	present	in	these	models	are	unable	to	be	reproduced	in	knock-
in	models	of	the	disease,	suggesting	they	are	simply	artefacts	as	a	result	of	protein	overexpression	
(Saito	et	al.,	2014).	However,	it	can	also	be	argued	that	APP	overexpression	is	not	artificial	since	
duplication	of	the	entire	APP	gene	causes	early-onset	familial	forms	of	AD	(McNaughton	et	al.,	2012)	
and	sufferers	of	Down’s	syndrome,	who	carry	an	extra	copy	of	chromosome	21	that	harbours	the	
gene,	develop	the	disease	(García-Alba	et	al.,	2019).	Nevertheless,	the	possibility	of	artefacts	in	our	
disease	model	must	be	taken	into	account,	but	the	fact	the	results	in	this	model	were	replicated	in	
our	knock-in	model	of	the	disease	suggests	they	are	not	simply	a	product	of	protein	overexpression.	
It	was	interesting	to	note	that	figure	5-1	A	demonstrates	all	neurons	in	the	field	of	view	transfected	
with	APPWT	had	reduced	GluA2	expression	levels	compared	to	control	neurons.	This	suggests	Aβ	
from	the	transfected	neuron	could	be	affecting	AMPAR	expression	in	neighbouring	cells.	Since	Aβ	is	
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secreted	via	exocytosis	into	the	extracellular	space,	its	affect	on	nearby	cells	isn’t	surprising	
(Bergmans	and	De	Strooper,	2010).	
Consistent	with	our	results,	a	previous	study	has	also	demonstrated	a	loss	of	GluA2	receptor	subunit	
expression	in	a	mouse	model	overexpressing	APPWT	(Simón	et	al.,	2009).	In	contrast	to	our	data	
however,	this	model	also	demonstrates	total	degradation	of	the	GluA1	receptor	subunit.	Beside	
from	the	fact	one	system	is	overexpressing	APPWT	in	a	transgenic	mouse	model	and	the	other	in	a	
neuronal	culture	model,	the	inconsistencies	could	arise	as	a	result	of	differences	in	the	extent	of	Aβ	
build-up.	Indeed,	Simón	and	colleagues	(2009)	demonstrate	that	in	both	5-	and	8-	month	old	APPWT	
mice,	barely	detectable	levels	of	Aβ42	were	present,	which	led	to	the	conclusion	that	the	pathological	
features	in	these	mice	were	unrelated	to	the	levels	of	Aβ.	Thus,	an	Aβ-independent	pathogenic	
pathway	with	mechanisms	distinct	from	our	model	is	probably	to	blame	for	the	inconsistencies.	
Few	studies	have	directly	investigated	the	consequences	of	overexpressing	human	APPWT	in	neuronal	
cell	culture	on	AMPAR	expression,	except	Hsieh	et	al	(2006)	who	examined	its	effects	on	endogenous	
GluA1	and	GluA2	receptor	subunit	levels.	It	was	established	that	APPWT	overexpression	did	not	
significantly	affect	endogenous	GluA1	or	GluA2	expression	levels,	a	surprising	contrast	to	our	results.	
However,	the	differences	in	conclusions	between	our	work	and	the	previous	study	may	be	explained	
by	differences	in	methodology.	Indeed,	Hsieh	et	al	(2006)	used	Sindbis	viral	infection	to	deliver	the	
APP	constructs	into	organotypic	slices,	whereas	we	used	lipofection	in	dissociated	neuronal	cultures.	
Furthermore,	whereas	subunit	expression	in	our	model	was	measured	48	hours	post-transfection,	
Hsieh	and	colleagues	measured	total	expression	levels	just	22-26	hours	post-transduction	(Hsieh	et	
al.,	2006).	Perhaps	Aβ	build-up	at	this	earlier	time-point	was	not	yet	sufficient	to	significantly	disrupt	
the	trafficking	of	GluA2/3	heteromers	towards	lysosomal	degradation.	Examining	AMPAR	expression	
at	a	series	of	intervals	would	help	determine	how	long	after	APPWT	transfection	we	can	begin	to	see	
changes	in	subunit	expression	levels,	in	order	to	establish	the	time-course	within	which	this	
phenomenon	occurs.		
	
5.4.3 APPSWE	expression	and	AMPARs	
	
Figure	5-3	B	demonstrated	that	endogenous	APP	could	be	successfully	knocked	down	in	cortical	
neuronal	cultures	using	rat	APP	shRNA,	and	both	APPWT	and	APPSWE	could	rescue	protein	expression.	
Since	APP	densitometry	was	not	significantly	different	from	Scr	control	levels,	this	indicated	that	the	
viruses	developed	by	our	lab	rescued	protein	expression	to	endogenous	levels,	thus	any	artefacts	
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that	could	arise	as	a	result	of	protein	overexpression	were	prevented	(Saito	et	al.,	2014).	All	
detectable	APP	in	the	APPWT	and	APPSWE	replacement	cultures	was	recombinant	(figure	5-3	E).		
Although	our	model	demonstrated	endogenous	expression	of	the	APP	mutant	APPSWE,	the	
expression	levels	of	Aβ	were	not	measured.	However,	previous	evidence	demonstrates	that	
accumulation	of	Aβ	is	most	likely	responsible	for	AD	phenotypes	in	this	model	(Almeida	et	al.,	2005).	
Indeed,	it	has	been	demonstrated	that	cultured	neurons	from	Tg2576	mice,	which	express	the	
APPSWE	double	mutation,	exhibit	a	significant	increase	in	Aβ	levels	(Takahashi	et	al.,	2004)	and	it	has	
also	been	demonstrated	that	inhibition	of	both	BACE1	and	γ-secretase,	which	block	the	generation	
of	Aβ,	reverse	AD	phenotypes	in	Tg2576	mice	(Ohno	et	al.,	2004;	Almeida	et	al.,	2005).	It	is	therefore	
likely	that	Aβ	accumulation	is	responsible	for	the	changes	in	AMPAR	expression	observed	in	our	
model,	however,	because	this	was	not	directly	measured	it	cannot	be	assumed.	
GluA2	levels	did	not	significantly	differ	between	the	Scr	control	and	Sh-APP	conditions	which	is	to	be	
expected.	Indeed,	since	under	healthy	conditions	the	majority	of	APP	is	cleaved	by	α-	followed	by	γ-
secretase	in	the	non-amyloidogenic	pathway	(O’Brien	and	Wong,	2011),	knocking	down	APP	would	
not	significantly	affect	these	negligible	levels	of	Aβ.	It	was,	however,	unexpected	that	the	Shres-
APPWT	condition	demonstrated	increased	GluA2	expression	in	comparison	to	the	Scr	control	and	Sh-
APP	conditions;	this	was	surprising	given	there	was	no	overexpression	of	APP	in	the	three	conditions	
and	therefore	no	increase	in	APP	amyloidogenic	processing.	It	could	be	that	the	myc	tag	on	APP	has	
some	uncharacterised	effect	on	AMPARs,	perhaps	indirectly	via	some	other	aspect	of	synaptic	
organisation.	Alternatively,	since	the	myc	tag	is	on	the	c-terminus	of	APP,	it	could	influence	the	
activity	of	downstream	APP	cleavage	products	which	might	influence	GluA2	receptor	trafficking.	
Indeed,	APP	cleavage	products	have	demonstrated	the	ability	to	modulate	neuronal	function	and	
circuit	activity	(Harris	et	al.,	2020).	
AMPAR	expression	levels	have	not	previously	been	explored	in	neuronal	cultures	directly	infected	
with	APPSWE,	but	there	is	a	study	investigating	subunit	expression	in	a	Tg2576	mouse	model.	
Consistent	with	our	results,	Almeida	et	al	(2005)	demonstrated	that	DIV12	cultured	neurons	from	
Tg2576	mice	exhibit	no	change	in	total	levels	of	the	GluA1	receptor	subunit.	This	supports	the	idea	
that	GluA1/2	heteromers	are	protected	from	the	effects	of	Aβ,	although	GluA2	receptor	subunit	
data	is	needed	to	confirm	this.	
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5.4.4 J20	mice	and	AMPARs	
	
Figure	5-6	B	and	D	demonstrated	that	J20	mouse	models	showed	no	significant	change	in	GluA1	or	
GluA2	expression	levels	compared	to	WT	control	mice.	Since	J20	mice	express	both	the	Indiana	
(APPV717F)	and	the	double	Swedish	mutation	(APPK670N/M671L),	this	model	is	associated	with	severe	
disease	pathology	(Saganich	et	al.,	2006;	Cheng	et	al.,	2007;	Wright	et	al.,	2013),	thus	it	is	surprising	
that	a	loss	of	GluA2	expression	is	not	witnessed	in	the	disease	state.	
To	the	best	of	our	knowledge,	only	one	study	to	date	has	examined	the	expression	of	AMPARs	in	J20	
mouse	models.	Here,	it	was	established	that	levels	of	both	GluA1	and	GluA2	were	reduced	in	the	
dentate	gyrus	of	J20	mice	compared	to	controls	(Palop	et	al.,	2007).	The	discrepancy	between	our	
results	and	the	results	of	the	previous	study	could	be	due	to	a	number	of	fundamental	differences	in	
the	methodology.	Indeed,	Palop	and	colleagues	(2007)	examined	mice	that	were	sacrificed	at	4-7	
months	of	age,	whereas	the	mice	we	investigated	were	16-18	months	of	age.	However,	this	is	
unlikely	to	account	for	the	observed	differences	since	firstly,	robust	Aβ	plaques	develop	in	J20	
models	at	5	to	7	months	of	age	meaning	this	pathological	hallmark	should	be	established	in	both	
sets	of	mice	(Mucke	et	al.,	2000);	and	secondly,	a	loss	of	subunit	expression	was	witnessed	in	the	
younger	mice,	so	it	would	be	expected	that	the	same	phenotype,	if	not	worse,	would	be	observed	in	
those	at	16-18	months	of	age.	The	most	likely	explanation	for	the	differences	in	the	two	sets	of	data	
is	that	Palop	and	colleagues	(2007)	examined	subunit	expression	specifically	in	the	dentate	gyrus	of	
the	hippocampus.	Given	disruption	to	AMPAR	trafficking	has	been	widely	demonstrated	in	this	brain	
region	(Almeida	et	al	2005;	Hsieh	et	al.,	2006;	Simón	et	al.,	2009;	Megill	et	al.,	2015)	this	might	be	
why	we	didn’t	witness	any	changes	in	our	model	of	the	cortex.		
Having	said	this,	results	from	our	previous	two	models	suggest	that	the	molecular	mechanisms	
responsible	for	GluA2	down-regulation	are	not	cell-type	specific	and	are	observed	in	both	
hippocampal	and	cortical	neuronal	cultures.	Thus,	an	alternative	explanation	could	be	due	to	the	
differences	in	APP	overexpression	witnessed	between	the	six	J20	mouse	brains.	Although	figure	5-5	
B	demonstrates	that	there	is	a	significant	increase	in	APP	expression	in	J20	models	compared	to	WT	
controls	as	a	whole,	there	is	a	huge	variation	in	the	levels	of	APP	overexpression	between	brains.	
Indeed,	only	two	J20	mice	demonstrate	dramatic	APP	overexpression,	with	two	mice	exhibiting	
negligible	overexpression.	It	is	unclear	why	there	is	such	a	variation	in	the	levels	of	APP	
overexpression	between	the	mice,	since	there	were	all	males	and	housed	in	the	same	conditions.	It	
could	be	that	we	needed	to	optimise	the	brain	homogenisation	process.	Although	Aβ	levels	were	not	
measured	here,	it’s	likely	that	in	mice	exhibiting	lower	levels	of	APP	overexpression,	there	is	not	a	
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significant	build-up	of	Aβ.	This	might	explain	why	changes	to	AMPAR	subunit	expression	were	not	
witnessed,	since	we	believe	that	it	is	the	build-up	of	Aβ	that	is	responsible	for	disruption	to	receptor	
trafficking.	It		
Additionally,	due	to	time	constraints,	we	only	had	an	n	of	3	for	our	experiments	so	the	fact	that	we	
did	not	witness	any	significant	differences	could	be	because	our	experiment	was	underpowered,	
especially	given	the	two-fold	change	in	figure	5-6.	More	repeats	would	be	needed	in	future	
investigations	and	it	would	also	be	interesting	to	analyse	GluA2/GluA1	subunit	ratios	to	show	any	
potential	changes	here.	
This	chapter	identified	two	models	of	AD	in	which	expression	of	the	GluA2	subunit	was	found	to	be	
reduced	in	the	disease	state.	Considering	reduced	subunit	expression	can	indicate	changes	to	
protein	degradation,	it	was	important	to	investigate	how	this	might	occur	through	the	examination	
of	neuronal	protein	degradation	pathways.	
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6 GLUA2	UNDERGOES	LYSOSOMAL	TARGETING	IN	RESPONSE	TO	APP	
OVEREXPRESSION	
6.1 AIMS	
	
Following	the	confirmation	that	GluA2	subunit	expression	was	reduced	in	neuronal	models	of	
amyloidopathy,	it	was	important	to	investigate	whether	this	could	be	explained	by	degradation	of	
GluA2-containing	AMPARs.	Thus,	the	trafficking	of	AMPARs	to	the	lysosomal	degradation	pathway	
was	examined	in	response	to	amyloidopathy.	Potential	molecular	mechanisms	responsible	were	also	
investigated	by	examining	cortactin	tyrosine	phophorylation.	It	was	hypothesised	that	APPWT	
overexpression	would	lead	to	an	increase	in	GluA2	lysosomal	targeting,	and	APPSWE	expression	would	
lead	to	an	increase	in	cortactin	tyrosine	phosphorylation.	
	
6.2 INTRODUCTION	
	
It	has	been	widely	demonstrated	that	AMPARs	are	lost	from	the	surface	membrane	in	response	to	
Aβ	(Hsieh	et	al.,	2006;	Zhao	et	al.,	2010;	Alfonso	et	al.,	2014).	Some	of	the	molecular	mechanisms	
elucidated	thus	far	suggest	Aβ	promotes	surface	receptor	loss	via	an	increase	in	AMPAR	endocytosis	
(Hsieh	et	al.,	2006;	Almeida	et	al.,	2005).	However,	another	mechanism	that	can	result	in	receptor	
loss	from	the	surface	is	a	disruption	to	trafficking	so	that	instead	of	being	recycled,	receptors	are	
targeted	to	lysosomes	where	they	are	subsequently	degraded.	Indeed,	once	internalised,	receptors	
are	trafficked	into	early	endosomes	(EEs)	from	which	they	can:	undergo	recycling	to	the	post-
synaptic	membrane	via	recycling	endosomes	(REs)	(van	der	Sluijs	and	Hoogenraad,	2011);	mature	
into	late	endosomes	(LEs)	and	fuse	with	lysosomes	for	degradation	(Hu	et	al.,	2015);	or	traffic	back	
to	the	trans-Golgi	network	for	further	PTMs	(Burd	and	Cullen,	2014).	A	complement	of	proteins	and	
PTMs	influence	the	endosomal	sorting	and	fate	of	internalised	receptors.	These	can	be	dysregulated	
in	the	disease	state	leading	to	aberrant	lysosomal	targeting	of	crucial	synaptic	proteins	(Parkinson	
and	Hanley,	2018).		
Recent	evidence	has	demonstrated	that	cortactin	maintains	surface	levels	of	GluA2/3	heteromers	by	
directing	receptors	away	from	lysosomes	(Parkinson	et	al.,	2018).	In	the	absence	of	a	cortactin-
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GluA2	interaction,	GluA2-containing	AMPARs	were	targeted	for	lysosomal	degradation.	The	
interaction	was	negatively	regulated	by	Src	family	kinase	(SFK)	phosphorylation	of	cortactin	at	
tyrosine	residues	Y421	and	Y466	(Parkinson	et	al.,	2018).		
Importantly,	emerging	evidence	has	identified	a	link	between	Aβ-mediated	toxicity	and	aberrant	SFK	
activity,	particularly	the	kinase	Fyn.	Indeed,	in	vitro	application	of	Aβ	has	been	shown	to	increase	
tyrosine	phosphorylation	of	an	array	of	proteins	in	various	preparations	(Luo	et	al.,	1995;	Bamberger	
et	al.,	2003;	Grace	and	Busciglio,	2003)	and	slices	from	Fyn	knockout	mice	are	spared	of	Aβ-
mediated	toxicity	(Lambert	et	al.,	1998).	Furthermore,	APP	transgenic	mouse	models	have	
demonstrated	that	Fyn	overexpression	both	accelerates	the	onset	of	cognitive	impairment	and	
promotes	Aβ-induced	synaptotoxicity,	a	phenomenon	which	can	be	rescued	by	Fyn	ablation	(Chin	et	
al.,	2004,	Chin	et	al.,	2005).		
Based	on	the	knowledge	that	increased	SFK	cortactin	phosphorylation	promotes	GluA2	lysosomal	
targeting	(Parkinson	et	al.,	2018)	and	aberrant	SFK	activity	has	been	reported	in	response	to	Aβ	
expression	(Luo	et	al.,	1995;	Bamberger	et	al.,	2003;	Grace	and	Busciglio,	2003),	it	was	hypothesised	
that	GluA2/3	heteromers	might	be	targeted	to	the	lysosome	in	response	to	amyloidopathy.	
Furthermore,	it	was	hypothesised	that	increased	tyrosine	phosphorylation	of	cortactin	might	be	a	
molecular	mechanism	involved	in	GluA2/3	lysosomal	targeting.		
Further	interest	for	the	lysosomal	degradation	of	GluA2-containing	AMPARs	in	AD	came	from	the	
evidence	that	oligomeric	Aβ	can	mimic	or	facilitate	the	induction	of	LTD	(Hsieh	et	al.,	2006;	Shanker	
et	al.,	2008;	Li	et	al.,	2009).	Indeed,	since	the	sorting	of	internalised	AMPARs	to	the	lysosome	is	a	key	
determinant	in	LTD	induction	(He	et	al.,	2009;	Fernández-Monreal	et	al.,	2012),	this	suggests	
aberrant	GluA2	lysosomal	targeting	may	prevail	in	models	of	amyloidopathy	and	contribute	to	
AMPAR	expression	loss.	Additionally,	it	has	previously	been	demonstrated	that	incubation	of	
hippocampal	neurons	with	Aβ	results	in	increased	expression	of	the	E3	ligase	Nedd4-1	(Zhang	et	al.,	
2018)	and	its	recruitment	to	dendritic	spines	(Rodrigues	et	al.,	2016).	Since	the	ubiquitin	system	can	
regulate	the	fate	of	AMPARs	by	promoting	degradation	via	the	lysosome	(Claque	and	Urbé,	2010)	
this	provides	additional	evidence	that	AMPAR	lysosomal	degradation	could	be	responsible	for	the	
loss	of	GluA2	expression,	although	proteasomal	degradation	is	also	a	possibility	here.	
Experiments	presented	in	this	chapter	investigated	the	lysosomal	targeting	of	the	AMPA	receptor	
subunits	GluA1	and	GluA2	in	response	to	amyloidopathy.	The	phosphorylation	of	cortactin	at	
tyrosine	residues	Y421	and	Y466	in	response	to	amyloidopathy	was	also	investigated	in	order	to	
explore	the	molecular	mechanism	that	might	be	responsible	for	GluA2/3	lysosomal	targeting.	
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6.3 RESULTS	
	
6.3.1 APPWT	overexpression	promotes	GluA2	lysosomal	targeting	
	
Antibody	feeding	assays	are	a	powerful	technique	used	to	track	the	movement	of	internalised	
endogenous	receptors	through	the	endosomal	pathway	and	have	been	successfully	used	before	to	
define	trafficking	mechanisms	in	cultured	neurons	(Lee,	Simonetta	and	Sheng,	2004;	Koszegi,	Fiuza	
and	Hanley,	2017;	Parkinson	et	al.,	2018).	Thus,	an	antibody	feeding	assay	was	used	to	track	the	
constitutive	movement	of	GluA2-containing	AMPARs	to	lysosomes	by	examining	co-localisation	
between	internalised	GluA2	and	the	lysosomal	marker	LAMP1.	In	chapter	3,	it	was	demonstrated	
that	overexpressing	APPWT	in	hippocampal	neuronal	cultures	resulted	in	reduced	GluA2	expression.	
This	made	it	an	appropriate	model	to	investigate	the	involvement	of	the	lysosomal	pathway	in	
GluA2-containing	AMPAR	expression	loss.		
Experiments	were	carried	out	in	hippocampal	neuronal	cultures	transfected	with	APPWT	or	APPMV	and	
returned	to	conditioned	media	for	20	or	45	minutes	following	antibody	incubation	to	allow	
constitutive	trafficking	of	surface	labelled	receptors	through	the	endosomal	system.	The	co-
localisation	of	internalised	GluA2	with	LAMP1	was	considered	an	indication	of	AMPAR	lysosomal	
targeting.		
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Figure	6-1	Overexpression	of	APPWT	results	in	GluA2	lysosomal	targeting	at	20	minutes.	
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(A) DIV13	primary	hippocampal	neurons	were	transfected	with	plasmids	encoding	APPWT-IRES-mCherry	or	APPMV-IRES-
mCherry	and	returned	to	conditioned	media	for	24	hours.	Cells	were	then	live	labelled	for	GluA2	and	returned	to	
conditioned	media	for	20	minutes	to	allow	trafficking	of	surface	labelled	GluA2	through	the	endosomal	system	before	
co-localisation	analysis	was	carried	out	between	internalised	GluA2	and	LAMP1.	Transfected	cells	were	identified	by	
mCherry	fluorescence	(red	channel).	The	magenta	channel	represents	staining	for	internalised	GluA2	and	the	cyan	
channel	for	LAMP1.	Full	image	scale	bar=30μm.	Panels	below	show	magnification	of	a	portion	of	dendrite	in	full	
images.	Magnified	panel	scale	bar=5μm.	
(B) Quantification	of	the	co-localisation	between	LAMP1	and	internalised	GluA2	at	20	minutes.	n=6.	Wilcoxon	matched-
pairs	signed	rank	test,	*p=0.0313.		
(C) Quantification	of	mean	fluorescence	intensity	of	internalised	GluA2	at	20	minutes	in	the	same	dendrites	analysed	in	
(B).	n=6.	Paired	two-tailed	student’s	t-test,	p=0.5642.		
(D) Quantification	of	mean	fluorescence	intensity	of	internalised	LAMP1	at	20	minutes	in	the	same	dendrites	analysed	in	
(B).	n=6.	Wilcoxon	matched-pairs	signed	rank	test,	p>0.9999.	
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Figure	6-2	Overexpression	of	APPWT		does	not	result	in	GluA2	lysosomal	targeting	at	45	minutes.	
90 
	
(A) DIV13	primary	hippocampal	neurons	were	transfected	with	APPWT-IRES-mCherry	or	APPMV-IRES-mCherry	and	
returned	to	conditioned	media	for	24	hours.	Cells	were	then	live	labelled	for	GluA2	and	returned	to	conditioned	
media	for	45	minutes	to	allow	trafficking	of	surface	labelled	GluA2	through	the	endosomal	system	before	co-
localisation	analysis	was	carried	out	between	internalised	GluA2	and	LAMP1.	Transfected	cells	were	identified	by	
mCherry	fluorescence	(red	channel).	The	magenta	channel	represents	staining	for	internalised	GluA2	and	the	cyan	
channel	for	LAMP1.	Full	image	scale	bar=30μm.	Panels	below	show	magnification	of	a	portion	of	dendrite	in	full	
images.	Magnified	panel	scale	bar=5μm.	
(B) Quantification	of	the	co-localisation	between	LAMP1	and	internalised	GluA2	at	45	minutes.	n=6.	Wilcoxon	
matched-pairs	signed	rank	test,	p=0.8438.	
(C) Quantification	of	mean	fluorescence	intensity	of	internalised	GluA2	at	45	minutes	in	the	same	dendrites	analysed	
in	(B).	n=6.	Paired	two-tailed	student’s	t-test,	p=0.2097.	
(D) Quantification	of	mean	fluorescence	intensity	of	internalised	LAMP1	at	45	minutes	in	the	same	dendrites	analysed	
in	(B).	n=6.	Wilcoxon	matched-pairs	signed	rank	test,	p=0.4527.	
	
Figure	6-1	B	demonstrated	that	20	minutes	after	internalisation	from	the	cell	surface,	APPWT	
overexpression	caused	a	small	but	significant	increase	in	the	Pearson’s	correlation	co-efficient	
between	internalised	GluA2	and	LAMP1	compared	to	APPMV	control.	These	results	suggest	that	
APPWT	overexpression	caused	a	loss	of	total	GluA2	by	increasing	the	lysosomal	targeting	of	GluA2-
containing	AMPARs.	45	minutes	after	internalisation	from	the	cell	surface,	the	Pearson’s	correlation	
co-efficient	was	indistinguishable	between	the	two	conditions,	indicating	no	difference	in	
GluA2/LAMP1	co-localisation	(figure	6-2	B).	A	likely	explanation	for	this	is	that	the	GluA2	trafficked	
to	lysosomes	as	a	consequence	of	APPWT	expression	had	been	subjected	to	lysosomal	degradation	
between	20	and	45	minutes.		
Despite	the	fact	that	Pearson’s	correlation	coefficient	is	robust	to	differences	in	signal	intensity	
(Dunn,	Kamocka	and	McDonald,	2011),	it	was	of	interest	to	determine	whether	levels	of	internalised	
GluA2	or	LAMP1	changed	between	the	APPWT	and	APPMV	conditions.	Figure	6-1	C	and	D	demonstrate	
no	differences	in	signal	intensity	for	either	GluA2	or	LAMP1	which	further	rules	out	the	results	being	
due	to	changes	in	intensities	of	either	channel.	These	data	are	of	additional	importance	because:	
internalised	GluA2	intensity	provides	an	indication	of	any	change	to	endocytosis,	which	has	been	
demonstrated	in	response	to	amyloidopathy	and	could	influence	trafficking	to	lysosomes	(Hsieh	et	
al.,	2006);	and	LAMP1	intensity	can	indicate	whether	or	not	changes	to	lysosomes	are	occurring	in	
response	to	Aβ,	which	has	also	been	demonstrated	(Knauer	et	al.,	1992;	Yang	et	al.,	1998;	Ditaranto,	
Tekirian	and	Yang,	2001;	Liu	et	al.,	2010b).	
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Total	expression	levels	of	GluA1	did	not	change	in	cells	overexpressing	APPWT	compared	to	APPMV,	
which	suggests	there	is	no	change	in	GluA1	subunit	sorting	to	degradative	pathways	in	response	to	
Aβ.	This	was	verified	by	investigating	the	effect	of	APPWT	overexpression	on	GluA1	lysosomal	
targeting.	Hippocampal	neurons	were	cultured,	transfected	and	prepared	for	antibody	feeding	
immunocytochemistry	as	before	(figure	6-2	A).	Figures	6-3	B	and	6-4	B	demonstrate	that	at	both	20	
minutes	and	45	minutes	there	was	no	significant	difference	in	Pearson’s	correlation	coefficient	
between	cells	overexpressing	APPWT	and	APPMV,	suggesting	no	increase	in	lysosomal	degradation	of	
GluA1-containing	AMPARs.	Thus,	APPWT	overexpression	does	not	influence	GluA1	trafficking	to	
lysosomes.	
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Figure	6-3	Overexpression	of	APPWT	does	not	result	in	GluA1	lysosomal	targeting	at	20	minutes.	
(A) DIV13	primary	hippocampal	neurons	were	transfected	with	APPWT-IRES-mCherry	or	APPMV-IRES-mCherry	and	
returned	to	conditioned	media	for	24	hours.	Cells	were	then	live	labelled	for	GluA1	and	returned	to	conditioned	
media	for	20	minutes	to	allow	trafficking	of	surface	labelled	GluA1	through	the	endosomal	system	before	co-
localisation	analysis	was	carried	out	between	internalised	GluA1	and	LAMP1.	Transfected	cells	were	identified	by	
mCherry	fluorescence	(red	channel).	The	magenta	channel	represents	staining	for	internalised	GluA1	and	the	cyan	
channel	for	LAMP1.	Full	image	scale	bar=30μm.	Panels	below	show	magnification	of	a	portion	of	dendrite	in	full	
images.	Magnified	panel	scale	bar=5μm.		
(B) Quantification	of	the	co-localisation	between	LAMP1	and	internalised	GluA1	at	20	minutes.	n=6.	Wilcoxon	
matched-pairs	signed	rank	test,	p=0.8438.	
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Figure	6-4	Overexpression	of	APPWT	does	not	result	in	GluA1	lysosomal	targeting	at	45	minutes.	
(A) DIV13	primary	hippocampal	neurons	were	transfected	with	APPWT-IRES-mCherry	or	APPMV-IRES-mCherry	and	
returned	to	conditioned	media	for	24	hours.	Cells	were	then	live	labelled	for	GluA1	and	returned	to	conditioned	
media	for	45	minutes	to	allow	trafficking	of	surface	labelled	GluA1	through	the	endosomal	system	before	co-
localisation	analysis	was	carried	out	between	internalised	GluA1	and	LAMP1.	Transfected	cells	were	identified	by	
mCherry	fluorescence	(red	channel).	The	magenta	channel	represents	staining	for	internalised	GluA1	and	the	cyan	
channel	for	LAMP1.	Full	image	scale	bar=30μm.	Panels	below	show	magnification	of	a	portion	of	dendrite	in	full	
images.	Magnified	panel	scale	bar=5μm.		
(B) Quantification	of	the	co-localisation	between	LAMP1	and	internalised	GluA1	at	45	minutes.	n=6.	Wilcoxon	
matched-pairs	signed	rank	test,	p=0.6875.		
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6.3.2 Leupeptin	restores	GluA2/LAMP1	co-localisation	at	45	minutes	after	internalisation	from	the	
cell	surface	
	
GluA2/LAMP1	co-localisation	was	indistinguishable	between	cells	overexpressing	APPWT	and	APPMV	at	
45	minutes	after	internalisation	from	the	cell	surface.	To	test	whether	this	was	due	to	lysosomal	
degradation	of	GluA2	at	this	later	time	point,	cultures	were	treated	with	leupeptin,	a	cell-permeable	
protease	inhibitor	that	inhibits	cysteine,	serine	and	threonine	peptidases	(Chu	et	al.,	1998).	Treating	
cultures	with	leupeptin	blocks	lysosomal	protein	hydrolysis	and	therefore	should	prevent	
degradation	of	GluA2-containing	AMPARs,	restoring	the	increase	in	GluA2/LAMP1	co-localisation	
seen	with	APPWT	at	20	minutes.	Experiments	were	carried	out	as	before	except	hippocampal	
neuronal	cultures	were	treated	with	100 μg/ml	leupeptin	for	3	hours	prior	to	and	during	GluA2	
antibody	incubation	and	trafficking.		
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Figure	6-5	Leupeptin	restores	GluA2/LAMP1	co-localisation	at	45	minutes	after	internalisation	from	the	cell	surface.	
(A) DIV13	primary	hippocampal	neurons	were	transfected	with	APPWT-IRES-mCherry	or	APPMV-IRES-mCherry	and	
returned	to	conditioned	media	for	21	hours.	Cultures	were	treated	with	100 μg/ml	leupeptin	3	hours	prior	to	and	
during	primary	antibody	incubation	and	trafficking.	Cells	were	live	labelled	for	GluA2	and	returned	to	conditioned	
media	for	45	minutes	to	allow	trafficking	of	surface	labelled	GluA2	through	the	endosomal	system	before	co-
localisation	analysis	was	carried	out	between	internalised	GluA2	and	LAMP1.	Transfected	cells	were	identified	by	
mCherry	fluorescence	(red	channel).	The	magenta	channel	represents	staining	for	internalised	GluA1	and	the	cyan	
channel	for	LAMP1.	Full	image	scale	bar=30μm.	Panels	below	show	magnification	of	a	portion	of	dendrite	in	full	
images.	Magnified	panel	scale	bar=5μm.	
(B) Quantification	of	the	co-localisation	between	LAMP1	and	internalised	GluA2	at	45	minutes	in	the	presence	of	
leupeptin.	n=6.	Wilcoxon	matched-pairs	signed	rank	test,	*p=0.0313.		
96 
	
	
Figure	6-6	Leupeptin	treatment	abolishes	GluA2/LAMP1	co-localisation	at	20	minutes	after	internalisation	from	the	cell	
surface.	
(A) DIV13	primary	hippocampal	neurons	were	transfected	with	APPWT-IRES-mCherry	or	APPMV-IRES-mCherry	and	
returned	to	conditioned	media	for	21	hours.	Cultures	were	treated	with	100 μg/ml	leupeptin	3	hours	prior	to	and	
during	primary	antibody	incubation	and	trafficking.	Cells	were	live	labelled	for	GluA2	and	returned	to	conditioned	
media	for	20	minutes	to	allow	trafficking	of	surface	labelled	GluA2	through	the	endosomal	system	before	co-
localisation	analysis	was	carried	out	between	internalised	GluA2	and	LAMP1.	Transfected	cells	were	identified	by	
mCherry	fluorescence	(red	channel).	The	magenta	channel	represents	staining	for	internalised	GluA1	and	the	cyan	
channel	for	LAMP1.	Full	image	scale	bar=30μm.	Panels	below	show	magnification	of	a	portion	of	dendrite	in	full	
images.	Magnified	panel	scale	bar=5μm.	
(B) Quantification	of	the	co-localisation	between	LAMP1	and	internalised	GluA2	at	20	minutes	in	the	presence	of	
leupeptin.	n=6.	Wilcoxon	matched-pairs	signed	rank	test,	p=0.5625.		
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Figure	6-5	B	demonstrated	that	in	the	presence	of	leupeptin,	at	45	minutes	after	receptor	
internalisation	from	the	cell	surface,	APPWT	overexpression	caused	an	increase	in	the	Pearson’s	
correlation	co-efficient	between	internalised	GluA2	and	LAMP1.	Thus,	leupeptin	restored	the	
increase	in	GluA2/LAMP1	co-localisation,	supporting	the	finding	that	APPWT	overexpression	causes	
degradation	of	GluA2-containing	AMPARs	in	lysosomes	between	20	and	45	minutes.	Surprisingly,	
leupeptin	abolished	the	increase	in	Pearson’s	correlation	co-efficient	at	20	minutes	that	was	
observed	previously	following	APPWT	overexpression	(figure	6-6	B).	This	suggests	leupeptin	might	
have	off	target	effects	in	slowing	down	receptor	internalisation	and	trafficking	through	the	
endosomal	system	so	that	at	20	minutes,	GluA2-containing	AMPARs	were	not	yet	co-localised	with	
lysosomes.		
	
6.3.3 Knockdown	of	endogenous	APP	and	replacement	with	APPSWE	causes	an	increase	in	cortactin	
Y466	phosphorylation	
	
Overexpression	of	APPWT	demonstrated	that	GluA2-containing	AMPARs	were	selectively	targeted	to	
lysosomes	in	response	to	amyloidopathy.	It	was	therefore	of	interest	to	elucidate	the	molecular	
mechanisms	responsible.	Cortactin	can	be	phosphorylated	on	tyrosine	residues	421,	466	and	482	by	
SFKs,	which	regulate	its	ability	to	bind	interacting	proteins	(Huang	et	al.,	1997a;	Dudek	et	al.,	2002;	
Martinez-Quiles	et	al.,	2004;	Zhu	et	al.,	2007).	Importantly,	the	phosphorylation	of	cortactin	at	
residues	421	and	466	negatively	regulates	the	cortactin-GluA2	interaction	resulting	in	the	targeting	
of	GluA2-containing	AMPARs	for	lysosomal	degradation	(Parkinson	et	al.,	2018).	Since	enhanced	SFK	
activity	has	been	widely	demonstrated	in	AD	(Shirazi	and	Wood,	1993;	Lambert	et	al.,	1998;	Chin	et	
al.,	2004;	Chin	et	al.,	2005)	it	was	of	interest	to	investigate	the	tyrosine	phosphorylation	of	cortactin	
in	response	to	amyloidopathy.	
Although	lysosomal	targeting	of	GluA2	was	demonstrated	in	APPWT	overexpression	cultures,	due	to	
time	constraints	the	molecular	replacement	constructs	were	chosen	for	further	investigation	of	
GluA2	degradative	mechanisms.	It	was	demonstrated	in	chapter	3	that	the	replacement	of	
endogenous	APP	with	APPSWE	resulted	in	reduced	GluA2	expression,	therefore	this	was	an	
appropriate	model	to	investigate	possible	molecular	mechanisms	leading	to	GluA2-containing	
AMPAR	degradation.	Western	blotting	could	be	used	as	an	effective	technique	to	detect	
phosphorylated	levels	of	cortactin,	and	the	phospho-specific	antibodies	for	tyrosine	421	and	466	of	
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cortactin	had	previously	been	validated	(Zhou	et	al.,	2006b;	Tehrani	et	al.,	2007;	Sánchez,	Urrego	
and	Pardo,	2016;	Parkinson	et	al.,	2018).	Cortical	neuronal	cultures	were	infected	with	the	molecular	
replacement	constructs	as	before	and	lysed	4	days	later,	followed	by	immunoblotting	for	pY421-	and	
pY466-	cortactin.		
	
	
Figure	6-7	Knockdown	of	endogenous	APP	and	replacement	with	APPSWE		in	cortical	neuronal	cultures	causes	a	specific	
increase	in	pY466-cortactin	phosphorylation.	
DIV12-16	cortical	neurons	were	transduced	with	lentiviral	molecular	replacement	constructs	and	returned	to	
conditioned	media	for	4	days.	Cells	were	then	lysed	and	immunoblotted	using	the	indicated	antibodies.		
(A) Representative	Western	blots	of	pY466-cortactin	and	total	cortactin.		
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(B) Quantification	of	cortactin	phosphorylation	at	Y466.	Band	intensities	were	obtained	through	quantitative	
densitometry	and	pY466-cortactin	values	were	normalised	to	total	cortactin.	n=7.	One-way	ANOVA	with	
Bonferroni’s	test	for	multiple	comparisons,	*p=0.0308.	
(C) Representative	Western	blots	of	pY421-cortactin	and	total	cortactin.		
(D) Quantification	of	cortactin	phosphorylation	at	Y421.	Band	intensities	were	obtained	through	quantitative	
densitometry	and	pY421-cortactin	values	were	normalised	to	total	cortactin.	n=7.	Kruskal-Wallis	with	Dunn’s	
test	for	multiple	comparisons,	p=0.3567.	
	
Figure	6-7	B	demonstrated	that	cortactin	phosphorylation	at	Y466	was	increased	in	response	to	
APPSWE.	In	contrast,	cortactin	phosphorylation	at	Y421	was	not	significantly	affected	by	knockdown	
of	endogenous	APP	and	replacement	with	APPSWE	compared	to	APPWT	control	cells	(figure	6-7	D).	
Therefore,	modelling	amyloidopathy	led	to	the	selective	increase	in	cortactin	phosphorylation	at	
tyrosine	466.		
	
6.4 DISCUSSION	
	
6.4.1 Lysosomal	targeting	of	GluA2-containing	AMPARs	
	
Figure	6-1	B	showed	that	overexpression	of	amyloidogenic	APP	in	hippocampal	neuronal	cultures	
resulted	in	increased	co-localisation	between	GluA2	and	LAMP1	within	20	minutes,	which	strongly	
suggested	that	the	trafficking	of	GluA2-containing	AMPARs	to	the	lysosome	was	responsible	for	their	
reduced	expression.	Analysis	of	the	co-localisation	at	45	minutes	strengthened	the	conclusion	that	
GluA2-containing	receptors	were	indeed	being	degraded,	since	the	increased	co-localisation	
observed	at	20	minutes	returned	to	baseline	levels	at	45	minutes	(figure	6-2	B).	The	timing	for	
AMPARs	to	reach	lysosomal	compartments	was	quicker	than	the	trafficking	to	lysosomes	under	
basal	conditions	(Parkinson	et	al.,	2018),	but	similar	to	what	has	been	established	after	bath	
application	of	AMPA	and	NMDA	(Ehlers,	2000;	Lee,	Simonetta	and	Sheng,	2004),	which	was	to	be	
expected.	
No	change	in	GluA1/LAMP1	co-localisation	was	observed	between	APPWT	and	APPMV	(figure	6-3	B,	
figure	6-4	B),	which	was	to	be	expected	since	it	was	previously	demonstrated	in	figure	5-2	that	there	
was	no	significant	decrease	in	GluA1	expression	levels	in	this	model	of	amyloidopathy.	Given	that	
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the	majority	of	AMPARs	in	the	mature	hippocampus	are	made	up	of	GluA1/2	or	GluA2/3	heteromers	
(Wenthold	et	al.,	1996;	Lu	et	al.,	2009),	this	further	supports	the	view	that	it	is	GluA2/3	heteromers	
that	are	targeted	for	lysosomal	degradation	in	the	disease	state.	Additional	support	for	this	model	
comes	from	a	report	suggesting	that	the	GluA3	subunit	promotes	lysosomal	targeting	(Lee,	
Simonetta	and	Sheng,	2004)	and	evidence	that	mice	lacking	GluA3-containing	AMPARs	are	protected	
against	Aβ-induced	synaptic	deficits	(Reinders	et	al.,	2016).	Furthermore,	a	study	screening	for	gene-
expression	profiles	associated	with	mild	cognitive	impairment,	a	transitional	stage	between	aging	
and	AD,	highlighted	GluA3	as	having	a	strong	negative	correlation	with	cognitive	performance	
(Berchtold	et	al.,	2014).	Indeed,	it	may	be	the	case	that	the	GluA3	subunit	is	predominantly	
responsible	for	GluA2/3	lysosomal	sorting.	This	would	be	worth	studying	in	future	investigations.		
Although	significant	co-localisation	was	witnessed	between	internalised	GluA2	and	LAMP1	within	20	
minutes,	the	difference	in	mean	Pearson’s	co-efficient	between	cells	overexpressing	APPWT	and	
APPMV	cells,	and	thus	the	overall	effect	size,	was	small.	This	could	suggest	that	although	a	significant	
portion	of	GluA2-containing	AMPARs	are	targeted	for	lysosomal	degradation	in	response	to	Aβ,	this	
pathway	is	not	solely	responsible	for	the	loss	of	GluA2	expression	levels.	There	are	a	number	of	
reasons	why	this	could	be.	
There	exists	a	body	of	evidence	that	describes	abnormalities	in	the	endolysosomal	network	in	AD.	
Indeed,	a	striking	neuronal	pathology	in	the	disease	is	the	presence	of	autolysosomes	contained	
within	giant	neuritic	swellings,	which	suggests	the	elimination	of	substrates	from	these	lysosomes	is	
defective	(Nixon	et	al.,	2005).	Aβ42	aggregates	can	accumulate	in	lysosomes,	resulting	in	disruption	of	
the	endolysosomal	pathway	(Knauer	et	al.,	1992;	Ditaranto,	Tekirian	and	Yang,	2001;	Liu	et	al.,	
2010b),	disruption	to	the	lysosomal	membrane	proton	gradient	(Ditaranto,	Tekirian	and	Yang,	2001)	
and	a	loss	of	lysosomal	membrane	impermeability	which	precedes	cell	death	(Yang	et	al.,	1998).	
Since	we	modelled	amyloidopathy	in	our	experiments,	Aβ42	aggregates	could	have	resulted	in	
lysosomal	disruption	and	contributed	to	the	small	effect-size	of	GluA2-LAMP1	co-localisation.		
It	must	be	noted	that	in	the	early	stages	of	AD,	lysosomal	biogenesis	is	actually	up-regulated	in	
response	to	rab5-mediated	acceleration	of	endocytosis	(Cataldo	et	al.,	1995;	Bordi	et	al.,	2016)	as	
evidenced	by	growth	of	the	lysosomal	population,	activation	of	transcription	factors	that	regulate	
lysogenesis	and	the	expression	of	lysosomal	gene	targets	(Nixon	and	Cataldo,	2006;	Bordi	et	al.,	
2016).	Indeed,	it	is	not	until	later	on	that	lysosomes	become	dysfunctional,	as	reflected	by	their	
enlargement	as	they	accumulate	endocytic	substrates	(Nixon,	2017).	However,	in	our	model	there	
appeared	to	be	no	change	in	LAMP1	expression	levels	in	APPWT	neurons	compared	to	controls	(figure	
6-1	D,	figure	6-2	D)	indicating	that	lysosomal	biogenesis	was	not	exhibited	here.		
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AMPAR	degradation	occurs	not	only	via	endolysosomal	trafficking,	but	through	a	variety	of	other	
mechanisms	including	the	ubiquitin	proteasome	system	(UPS)	(Goo,	Scudder	and	Patrick,	2015).	
Indeed,	polyubiquitination	targets	receptors	for	degradation	by	the	26S	proteasome	(Claque	and	
Urbé,	2010).	Thus	proteosomal	degradation	could	also	be	responsible	for	the	loss	of	GluA2	
expression.	In	order	to	investigate	this,	GluA2	expression	levels	could	be	examined	after	treating	
neuronal	cultures	with	a	proteasome	inhibitor	such	as	MG-132,	which	blocks	the	proteolytic	activity	
of	the	26S	proteasome	complex	(Han	et	al.,	2009).	Indeed,	if	GluA2-containing	AMPARs	were	being	
degraded	via	the	UPS,	treatment	with	MG-132	would	result	in	a	smaller	effect	size	for	the	loss	of	
GluA2	expression.	Furthermore,	if	lysosomal	and	proteosomal	degradation	were	solely	responsible	
for	the	loss	of	GluA2	expression	in	this	model	of	amyloidopathy,	treating	cultures	with	both	MG-132	
and	leupeptin	would	result	in	the	loss	of	expression	being	eradicated.	Since	both	of	these	systems	
operate	downstream	of	AMPAR	ubiquitination,	which	is	upregulated	in	the	disease	state	(Rodrigues	
et	al.,	2016;	Guntupalli	et	al.,	2017;	Zhang	et	al.,	2018),	the	involvement	of	both	of	these	
degradation	pathways	is	likely.		
However,	there	is	also	evidence	of	proteasome	dysfunction	in	AD	pathogenesis.	Indeed,	a	reduction	
in	proteasome	activity	was	observed	in	post-mortem	brains	from	AD	patients	compared	to	control	
brains,	primarily	in	regions	crucial	for	long-term	memory	including	the	hippocampus	and	
parahippocampal	gyrus	(Keller,	Hanni	and	Markesbery,	2001),	and	in	vitro	evidence	demonstrates	
that	Aβ42	can	inhibit	proteasome	activity	to	the	same	extent	as	the	proteasomal	inhibitor	lactacystin	
(Oh	et	al.,	2005).	These	findings	should	be	taken	into	consideration	when	examining	the	involvement	
of	proteasome	degradation	in	the	loss	of	GluA2	expression.	
	
6.4.2 Leupeptin	and	lysosomal	sorting	
	
Leupeptin	is	a	cell-permeable	protease	inhibitor	that	inhibits	cysteine,	serine	and	threonine	
peptidases	(Chu	et	al.,	1998)	and	thus	should	prevent	the	degradation	of	GluA2-containing	AMPARs.	
Figure	6-5	B	demonstrated	that	application	of	leupeptin	restored	GluA2/LAMP1	co-localisation	at	45	
minutes,	which	helped	to	confirm	GluA2-containing	AMPARs	were	indeed	being	degraded.	
Surprisingly	however,	leupeptin	abolished	the	increase	in	co-localisation	at	20	minutes	(figure	6-6	B).	
It’s	possible	that	leupeptin	could	have	off	target	effects	that	slow	down	receptor	internalisation	or	
sorting,	so	that	at	20	minutes	GluA2/3	heteromers	were	not	yet	co-localised	with	lysosomes.	There	
is	little	literature	examining	the	effects	of	leupeptin	on	receptor	endocytosis	and	sorting	
mechanisms,	but	previous	evidence	in	mammalian	cells	has	demonstrated	a	decrease	in	the	amount	
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of	endocytosed	ferritin	ending	up	in	lysosomes	at	various	timepoints	in	leupeptin	treated	cells	
compared	to	controls	(Miki	and	Kugler,	1986).	Thus,	it’s	possible	that	trafficking	in	the	endosomal	
pathway	could	have	been	affected	by	leupeptin	in	this	experiment.	It	would	be	useful	to	employ	a	
different	inhibitor	of	lysosomal	degradation	such	as	bafilomycin	which	inhibits	vaculolar-type	H+-
ATPases	(Tapper	and	Sundler,	1995)	to	determine	whether	or	not	co-localisation	at	20	minutes	
remains	and	whether	the	results	are	due	to	leupeptin	interfering	with	endosomal	trafficking.	
	
6.4.3 Aβ	and	endocytosis	
	
Figure	6-1	C	and	6-2	C	demonstrated	that	there	was	no	difference	in	levels	of	internalised	GluA2	
between	cells	overexpressing	APPWT	and	control	cells	at	both	20	and	45	minutes.	This	suggests	that	
GluA2	endocytosis	per	se	is	unaffected	by	Aβ.	Other	studies,	however,	have	demonstrated	an	
increase	in	AMPAR	endocytosis	in	response	to	Aβ.	Indeed,	Hsieh	et	al	(2006)	demonstrated	that	
when	a	GluA2	mutant	that	couldn’t	undergo	AP2-mediated	endocytosis	was	co-expressed	with	
APPWT,	AMPA-mediated	transmission	was	no	different	to	cells	expressing	APPMV.	This	indicated	that	
Aβ	produced	by	APP	overexpression	induced	synaptic	depression	by	driving	endocytosis	of	AMPARs.	
It’s	likely	that	the	difference	in	conclusions	between	our	work	and	the	previous	study	are	due	to	the	
fact	the	GluA2	mutation	that	prevents	AP2-mediated	endocytosis	is	in	the	same	region	of	the	
protein	that	binds	cortactin.	Thus,	the	results	could	be	explained	by	an	occlusion	as	a	result	of	
disrupting	GluA2-cortactin	binding.	Furthermore,	there	were	marked	differences	in	the	methodology	
used.	Indeed,	we	directly	tested	GluA2	internalisation	using	antibody	feeding	assays	whereas	Hsieh	
et	al	measured	the	amplitude	and	inward	rectification	of	evoked	AMPAR	transmission	(Hsieh	et	al.,	
2006).		
Several	studies	have	demonstrated	that	application	of	Aβ40	and	Aβ42	to	hippocampal	neuronal	
cultures	reduce	surface	expression	of	GluA2	though	a	mechanism	that	is	dependent	on	PICK1.	
Indeed,	an	increase	in	GluA2	phosphorylation	at	Ser-880	has	been	demonstrated	(Liu	et	al.,	2010a),	
which	weakens	its	interaction	with	GRIP	and	allows	PICK1	to	bind	(Seidenman	et	al.,	2003).	Similarly,	
Alfonso	et	al	(2014)	demonstrated	a	loss	of	surface	GluA2	following	treatment	of	CT100,	the	
precursor	to	Aβ,	that	was	dependent	on	an	interaction	with	PICK1.	Since	PICK1	has	demonstrated	
involvement	in	both	the	endocytosis	and	endosomal	sorting	of	GluA2-containing	AMPARs	(Lu	and	
Ziff,	2005;	Sossa,	Court	&	Carroll,	2006;	Lin	and	Huganir,	2007;	Widagdo	et	al.,	2016;	Fiuza	et	al.,	
2017;	Koszegi,	Fiuza	and	Hanley,	2017),	it	might	be	that	both	mechanisms	contribute	to	the	
pathology	of	AD.	
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6.4.4 Cortactin	phosphorylation	in	response	to	amyloidopathy	
	
Figure	6-7	B	demonstrated	that	cortactin	phosphorylation	at	Y466	was	increased	in	response	to	the	
expression	of	APPSWE.	Phosphorylation	was	specific	to	this	tyrosine	residue	since	Y421	
phosphorylation	was	not	increased	in	this	model	(figure	6-7	D).	Y466	phosphorylation	levels	did	not	
significantly	differ	between	the	Scr	control,	Sh-APP	and	Shres-APPWT	conditions	which	is	to	be	
expected.	Indeed,	since	under	healthy	conditions	the	majority	of	APP	is	cleaved	by	α-	followed	by	γ-
secretase	in	the	non-amyloidogenic	pathway	(O’Brien	and	Wong,	2011),	knocking	down	APP	or	
expressing	it	at	endogenous	levels	would	not	significantly	affect	these	negligible	levels	of	Aβ	since	
there	is	no	overexpression	of	APP	or	increase	in	APP	amyloidogenic	processing.		
Cortactin	is	the	target	of	SFK	phosphorylation	on	residues	Y421,	Y466	and	Y482	(Huang	et	al.,	1997a;	
Huang	et	al.,	1998),	and	this	acts	to	regulate	a	number	of	cellular	events	(Huang	et	al.,	1997a;	Huang	
et	al.,	1997b;	Martinez-Quiles	et	al.,	2004;	Cao	et	al.,	2009;	Vivstein	and	Pthenveedu,	2014).	
Importantly,	the	phosphorylation	of	cortactin	C-terminal	tyrosine	residues	negatively	regulates	the	
lysosomal	targeting	of	GluA2-containing	AMPARs	(Parkinson	et	al.,	2018).	Indeed,	mutating	all	three	
tyrosines	on	cortactin	to	be	phospho-null	increases	GluA2	binding,	therefore	phosphorylation	at	one	
or	all	of	these	tyrosines	reduces	GluA2	binding	so	that	cortactin	can	no	longer	maintain	surface	
levels	of	GluA2/3	heteromers	and	receptors	are	targeted	to	lysosomes.	Since	our	data	suggest	that	
phosphorylation	of	cortactin	at	Y466	was	increased	in	response	to	amyloidopathy,	it	is	possible	that	
this	mechanism	contributes	to	GluA2/3	lysosomal	targeting	in	AD.	
	
6.4.5 Trafficking	of	GluA2/3	heteromers		
	
There	are	predominantly	two	distinct	populations	of	AMPARs	in	the	adult	hippocampus,	GluA1/2	
and	GluA2/3	(Wenthold	et	al.,	1996).	Since	we	demonstrated	that	there	was	no	significant	reduction	
in	GluA1	expression	levels	(figure	5-2	B,	figure	5-4	D)	and	no	significant	co-localisation	of	GluA1	with	
LAMP1	(figure	6-3	B,	figure	6-4	B),	the	results	suggest	that	trafficking	of	GluA1-containing	receptors	
are	not	disrupted	by	amyloidopathy.	Thus,	the	pool	of	GluA2	affected	in	the	disease	state	is	likely	to	
be	in	complex	with	GluA3.	Indeed,	in	a	previous	study,	knocking	down	cortactin	was	shown	to	
significantly	reduce	expression	of	GluA3	as	well	as	GluA2,	and	increase	the	co-localisation	of	GluA3	
and	GluA2	with	LAMP1,	suggesting	that	cortactin	is	essential	for	maintaining	surface	levels	of	
GluA2/3	heteromers	(Parkinson	et	al.,	2018).	This	supports	a	model	in	which	GluA2/3	heteromers	
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traffic	to	lysosomes	when	cortactin	is	phosphorylated	in	response	to	amyloidopathy.	As	mentioned	
previously,	the	GluA3	subunit	has	been	previously	shown	to	promote	lysosomal	targeting	(Lee,	
Simonetta	and	Sheng,	2004)	and	there	is	evidence	that	mice	lacking	GluA3-containing	AMPARs	are	
protected	against	Aβ-induced	synaptic	deficits	(Reinders	et	al.,	2016).	Thus,	it	may	be	the	case	that	
the	GluA3	subunit	is	predominantly	responsible	for	GluA2/3	lysosomal	sorting.	Previous	work	in	our	
lab	has	demonstrated	that	cortactin	can	bind	the	GluA3	C-terminal	tail.	It	would	be	interesting	to	
investigate	this	interaction	further	to	determine	whether	or	not	a	cortactin-GluA3	interaction	can	
also	regulate	GluA2/3	lysosomal	targeting,	and	whether	this	is	disrupted	in	the	disease	state.	
	
6.4.6 Fyn	kinase	in	AD	
	
A	variety	of	kinases	in	the	SFK	family	have	been	implicated	in	the	phosphorylation	of	cortactin,	such	
as	Fer,	Fyn,	Nck1,	Src	and	Syk	(Wu	and	Parsons,	1993;	Kim	and	Wong,	1998;	Gallet	et	al.,	1999;	Kapus	
et	al.,	2000;	Fan	et	al.,	2004;	Oser	et	al.,	2010).	However,	Fyn	kinase	is	of	particular	interest	in	this	
model	since	it	has	previously	been	implicated	in	the	phosphorylation	of	cortactin	(Kapus	et	al.,	2000;	
Huang	et	al.,	2003;	Janjanam	and	Rao,	2016)	and	it	has	demonstrated	aberrant	activity	in	response	
to	Aβ.	Indeed,	the	first	evidence	for	a	direct	involvement	of	Fyn	in	AD	came	in	1998	when	slices	from	
Fyn	knockout	mice	were	spared	of	Aβ-mediated	toxicity	(Lambert	et	al.,	1998),	and	since	then	APP	
transgenic	mouse	models	have	demonstrated	that	Fyn	overexpression	promotes	Aβ-induced	
synaptotoxicity,	a	phenomenon	which	can	be	rescued	by	Fyn	ablation	(Chin	et	al.,	2004,	Chin	et	al.,	
2005).	Furthermore,	exposing	cultured	neurons	to	Aβ	resulted	in	increased	levels	of	phosphorylated	
Fyn,	and	Fyn	kinase	was	required	for	Aβ-induced	spine	loss	(Um	et	al.,	2012).	The	robust	evidence	
for	the	aberrant	activation	of	Fyn	in	response	to	amyloidopathy	suggests	that	this	specific	member	
of	the	SFK	family	could	be	responsible	for	the	increased	cortactin	Y466	phosphorylation	in	the	
disease	state.		
This	chapter	demonstrated	that	GluA2-containing	AMPARs	are	targeted	for	lysosomal	degradation	
following	APPWT	overexpression.	However,	the	overall	size	of	this	effect	was	small,	possibly	due	to	
lysosomal	dysfunction	that	can	occur	following	Aβ	pathology	(Knauer	et	al.,	1992;	Yang	et	al.,	1998;	
Ditaranto,	Tekirian	and	Yang,	2001;	Liu	et	al.,	2010b)	or	because	of	the	involvement	of	additional	
degradative	systems	such	as	the	UPS	(Claque	and	Urbé,	2010).	Nevertheless,	cortactin	
phosphorylation	was	increased	in	response	to	APPSWE	expression,	specifically	at	residue	Y466.	Since	
cortactin	Y466	phosphorylation	disrupts	the	cortactin-GluA2	interaction	and	the	maintenance	of	
GluA2/3	surface	levels	(Parkinson	et	al.,	2018),	the	results	suggest	that	this	mechanism	could	be	
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operating	in	response	to	amyloidopathy	to	increase	GluA2/3	lysosomal	targeting.	The	aberrant	
activation	of	Fyn	kinase	has	been	previously	demonstrated	in	response	to	Aβ	(Lambert	et	al.,	1998;	
Chin	et	al.,	2004,	Chin	et	al.,	2005;	Um	et	al.,	2012)	and	fyn	kinase	has	previously	been	implicated	in	
the	phosphorylation	of	cortactin	(Kapus	et	al.,	2000;	Huang	et	al.,	2003;	Janjanam	and	Rao,	2016),	
making	it	likely	that	this	kinase	is	responsible	for	increased	cortactin	phosphorylation	in	the	disease	
state.	
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7 GENERAL	DISCUSSION	
	
7.1 SUMMARY	
	
The	data	presented	in	this	thesis	demonstrate	that	there	is	a	reduction	in	the	expression	of	the	
AMPAR	subunit	GluA2	in	response	to	amyloidopathy.	The	results	suggest	Aβ	reduces	the	efficiency	
of	GluA2-containing	AMPAR	recycling,	so	that	these	receptors	are	sorted	into	lysosomes	where	the	
cargo	is	degraded.	The	data	also	demonstrate	that	there	is	an	increase	in	cortactin	phosphorylation	
at	residue	Y466	in	response	to	amyloidopathy,	which	suggests	that	Aβ	could	be	causing	AMPAR	
lysosomal	targeting	through	the	disruption	of	the	cortactin-GluA2	interaction,	which	functions	to	
maintain	surface	levels	of	GluA2/3	heteromers	(Parkinson	et	al.,	2018)	(figure	7-1).	This	work	
supports	previous	observations	that	AMPARs	are	lost	from	synapses	in	AD	models	(Hsieh	et	al.,	
2006;	Liu	et	al.,	2010;	Zhao	et	al.,	2010;	Miñano-Molina	et	al.,	2011;	Alfonso	et	al.,	2014)	and	that,	
generally	speaking,	there	is	a	reduction	in	AMPAR	protein	levels	in	post-mortem	AD	brains	
compared	to	controls	(Armstrong	et	al.,	1994;	Yasuda	et	al.,	1995;	Ikonomovic	et	al.,	1997;	Carter	et	
al.,	2004),	and	describes	the	first	identified	mechanism	for	the	loss	of	AMPAR	subunit	expression	in	
the	disease	state.	The	wider	implications	and	future	directions	that	these	results	present	will	be	
discussed	below.	
	
Figure	7-1	Schematic	of	the	proposed	role	of	Aβ	in	disrupting	AMPAR	trafficking.	
Under	healthy	conditions,	a	strictly	regulated	balance	of	constitutive	AMPAR	internalisation	and	recycling	maintains	a	
constant	number	of	AMPARs	at	the	post-synaptic	membrane.	Most	endocytic	events	are	likely	to	result	in	their	return	to	the	
plasma	membrane.	However,	a	number	of	these	events	will	result	in	AMPAR	degradation,	with	EEs	maturing	into	late	
endosomes	and	lysosomes.	The	degraded	receptors	are	presumably	replaced	by	newly	synthesised	AMPARs	from	the	
biosynthetic	machinery.	The	results	presented	in	this	thesis	indicate	that	Aβ	functions	to	disrupt	the	efficient	recycling	of	
AMPARs	back	to	the	synapse.	Indeed,	there	is	a	restriction	in	AMPAR	recycling	which	is	thought	to	be	mediated	by	GluA2-
containing	receptors.	Aβ	can	activate	SFKs,	which	phosphorylate	cortactin	and	cause	the	dissociation	between	cortactin	and	
107 
	
GluA2-containing	AMPARs.	This	results	in	less	efficient	GluA2-containing	AMPAR	recycling,	resulting	in	more	lysosomal	
AMPAR	degradation.		
	
7.2 WIDER	IMPLICATIONS	AND	FUTURE	DIRECTIONS	
	
7.2.1 Modelling	Alzheimer’s	disease	
	
Experimental	models	of	AD	are	vital	to	better	understand	the	pathophysiology	of	the	disorder	and	
for	testing	novel	therapeutics.	However,	success	in	AD	clinical	trials	has	been	limited	thus	far	due	to	
poor	translation	of	successful	preclinical	testing	in	animal	models	into	efficacious	treatments	(Banik	
et	al.,	2015).	A	plethora	of	models	exist	encompassing	both	transgenic	mice	and	in	vitro	brain	tissue.	
Since	each	model	replicates	different	pathological	hallmarks	of	the	disease,	gaining	consistent	
results	has	proved	troublesome.	In	this	thesis,	AMPAR	subunit	expression	was	examined	in	3	models	
of	AD:	the	overexpression	of	APPWT	in	neuronal	culture,	the	expression	of	APPSWE	in	neuronal	culture	
and	the	J20	transgenic	mouse	model.	
In	the	past,	researchers	have	struggled	to	generate	models	of	AD	that	overproduce	Aβ	without	
overexpressing	APP,	therefore	in	order	to	mimic	Aβ	pathology	many	research	groups	have	utilised	
models	that	overexpress	human	WT	APP	(Kamenetz	et	al.,	2003;	Hsieh	et	al.,	2006;	Simón	et	al.,	
2009)	or	APP	with	human	mutations	(Gu,	Liu	and	Yan,	2008;	Cantanelli	et	al.,	2014).	However,	
increasing	gene	expression	beyond	physiological	levels	can	introduce	artefacts	(Kuang	et	al.,	2006).	
Thus,	some	researchers	believe	that	APP	overexpression	is	an	artificial	means	to	model	AD.	In	order	
to	overcome	these	issues,	our	lab	developed	a	model	of	AD	that	replaces	endogenous	APP	with	a	
clinically	relevant	familial	mutation,	APPSWE,	in	culture.	During	this	project,	we	then	developed	a	
control	by	cloning	a	virus	that	replaces	the	endogenous	protein	with	APPWT.	This	allowed	us	to	use	
these	viruses	for	the	first	time	to	explore	molecular	mechanisms	of	the	disease.	It	will	be	vital	to	
confirm	that	the	APPSWE	is	overproducing	Aβ42	in	future	studies	by	using	an	Aβ-production	assay	of	
culture	media	with	anti-Aβ	antibodies,	but	this	novel	approach	to	model	amyloidopathy	shows	
promise	as	a	cell	culture	model	of	the	disease.		
Transgenic	mouse	models	dominate	approaches	to	the	animal	modelling	of	AD,	since	they	allow	
many	critical	aspects	of	the	disease	to	be	reproduced	through	the	expression	of	familial	genetic	
mutations.	However,	as	a	complex	disorder,	AD	is	a	polygenic	and	multifactorial	disease	in	which	
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hundreds	of	defective	genes	may	contribute	to	its	pathogenesis	(Cacabelos	et	al.,	2014).	As	such,	the	
exact	pathology	and	phenotype	of	each	transgenic	strain	depends	on	the	familial	AD	(fAD)	mutation,	
the	promoter	used	and	the	background	mouse	strain	(Drummond	and	Wisniewski,	2017).	Indeed,	
the	degree	to	which	each	model	is	characterised	in	terms	of	the	presence	of	plaques,	gliosis,	
neurofibrillary	tangles,	neurodegeneration,	synaptic	failure	and	the	extent	of	cognitive	impairment	
varies	greatly	(Higgins	and	Jacobsen,	2003).	Thus,	although	J20	models	in	this	instance	did	not	
display	AMPAR	expression	loss,	this	phenotype	has	been	demonstrated	in	other	transgenic	strains	
(Baglietto-	Almeida	et	al.,	2005;	Zhang	et	al.,	2011;	Cantanelli	et	al.,	2014;	Vargas	et	al.,	2018).	It	
might	be	that	the	specific	genetic	make-up	of	the	J20	strain	is	less	vulnerable	to	AMPAR	pathology,	
although	the	results	could	have	been	due	to	negligible	levels	of	APP	overexpression	in	some	of	the	
transgenic	mouse	brains.		
Since	the	vast	majority	of	AD	transgenic	models	have	pathology	that	is	dependent	on	the	expression	
of	fAD	mutations	and	most	AD	clinical	trials	are	conducted	in	sporadic	AD	(sAD)	patients	with	
pathogenesis	that	has	distinctions	from	fAD,	this	represents	one	stumbling	block	for	the	
translatability	of	success	(Drummond	and	Wisniewski,	2017).	Indeed,	developing	a	practical	and	
widely	available	model	of	sAD	would	be	indispensable	for	understanding	molecular	mechanisms	and	
advancing	pre-clinical	studies,	and	it	would	be	useful	to	examine	whether	AMPAR	pathology	exists	
here.	
One	way	to	do	this	could	be	through	the	use	of	induced	pluripotent	stem	cells	(iPSCs).	Indeed,	since	
their	discovery	in	2006	by	Yamanaka	and	colleagues,	much	progress	has	been	made	to	develop	
clinically	relevant	cell	culture	systems	(Takahashi	and	Yamanaka,	2006).	The	technique	allows	a	
patient’s	somatic	cells	to	be	reprogrammed	to	a	pluripotent	state	by	the	forced	expression	of	a	set	
of	transcription	factors	(Majolo	et	al.,	2019)	and	was	implemented	in	AD	for	the	first	time	in	2011	
with	the	successful	differentiation	of	these	cells	into	neurons	(Yagi	et	al.,	2011;	Yahata	et	al.,	2011).	
iPSCs	offer	great	potential	to	model	AD	in	vitro	since	they	can	be	generated	from	both	sAD	and	fAD	
patients	and	could	allow	treatment	to	be	individualised	based	on	the	behaviour	of	the	cellular	model	
(Majolo	et	al.,	2019).	Furthermore,	genome	editing	such	as	clustered	regularly	interspaced	short	
palindromic	repeats	(CRISPR)	can	be	used	to	correct	mutations	in	cells	from	fAD	patients	or	to	
introduce	mutations	into	cells	from	healthy	control	subjects	(de	Leeuw	and	Tackenberg,	2019).	Even	
sAD	cases	can	be	modelled	by	introducing	AD	risk	genes	such	as	APOE.	Indeed,	iPSCs	provide	a	
platform	to	better	understand	disease	mechanisms	in	human	cells	and	discover	novel	therapeutics	
(de	Leeuw	and	Tackenberg,	2019).		
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7.2.2 Reduced	GluA2	expression	in	response	to	amyloidopathy	
	
Along	with	an	overall	reduction	in	synaptic	AMPAR	number,	one	of	the	possible	outcomes	of	the	
specific	loss	of	GluA2/3	heteromers	is	the	reduction	in	GluA2	content	at	the	synaptic	plasma	
membrane	and	the	consequent	expression	of	CP-AMPARs.	The	mechanisms	by	which	CP-AMPARs	
contribute	to	neurodegeneration	in	AD	have	not	been	elucidated,	but	since	under	physiological	
conditions	CP-AMPARs	appear	only	transiently	in	response	to	synaptic	activity	(Plant	et	al.,	2006)	it	is	
likely	that	aberrant	activation	of	these	receptors	in	the	disease	state	leads	to	excitotoxicity,	a	pivotal	
catalyst	for	the	onset	of	pathology.	
For	future	directions	of	this	thesis,	it	would	be	useful	to	examine	CP-AMPAR	expression	and	
insertion	in	our	cell	culture	models.	This	would	provide	further	support	for	a	model	in	which	GluA2-
containing	AMPARs	are	targeted	for	lysosomal	degradation	in	response	to	Aβ,	leaving	GluA2-lacking	
CP-AMPARs	to	be	inserted	at	the	surface.	The	incorporation	of	CP-AMPARs	at	the	surface	membrane	
is	accompanied	by	an	increase	in	inward	rectification,	a	well	established	assay	for	the	absence	of	
GluA2-containing	AMPARs	(Hume,	Dingledine	and	Heinemann,	1991).	Recording	AMPAR-mediated	
EPSCs	in	hippocampal	brain	slices	expressing	amyloidogenic	APP	would	determine	the	extent	of	
inward	rectification	in	their	current-voltage	relationships.	The	presence	of	this	distinct	
electrophysiological	phenotype	would	provide	further	support	for	the	expression	of	GluA2-lacking	
CP-AMPARs	at	the	cell	surface.	
	
7.2.3 Mechanisms	of	GluA2	expression	loss		
	
The	recycling	of	receptors	to	the	plasma	membrane	is	recognised	as	a	complex	process	that	consists	
of	both	sequence-dependent,	actively-regulated	and	passive	sequestration	of	cargo	into	tubular	
domains	on	early	endosomes	(EEs)	(Puthenveedu	et	al.,	2010).	There	is	significant	overlap	between	
endolysosomal	and	ubiquitin-mediated	degradation,	and	the	dysregulation	of	these	systems	has	
been	consistently	observed	in	neurodegenerative	diseases	(Nedelsky,	Todd	and	Taylor,	2008;	Lee,	
Lee	and	Rubinsztein,	2013).	Indeed,	other	than	AD,	endosomal	dysfunction	is	an	early	indicator	for	a	
number	of	neurodegenerative	diseases	such	as	Parkinson’s	disease	(Schreij,	Fon	and	Mcpherson,	
2015),	Niemann-Pick	type	C1	(D’Arcangelo	et	al.,	2011;	Rabenstein	et	al.,	2017)	and	
neuropathologies	such	as	ischemia	(Yuan,	Liu	and	Hu,	2017).	This	thesis	proposes	a	novel	mechanism	
of	endolyosomal	dysfunction	in	AD,	whereby	Aβ	reduces	the	efficiency	of	GluA2-containing	AMPAR	
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recycling,	so	that	these	receptors	are	sorted	into	LEs	and	lysosomes	where	the	cargo	is	degraded.	As	
a	result,	fewer	receptors	are	recycled	back	to	the	post-synaptic	membrane	via	REs.	In	order	to	
extend	our	investigations	in	the	future,	this	hypothesis	could	be	further	tested	by	examining	AMPAR	
localisation	in	other	endosomal	compartments	for	example	those	positive	for	the	recycling	
endosomal	marker,	Rab11.	Indeed,	if	amyloidopathy	did	regulate	GluA2-containing	AMPAR	
endolysosomal	targeting,	these	experiments	would	be	expected	to	show	a	decreased	co-localisation	
between	internalised	GluA2	and	Rab11.	
Although	it	was	demonstrated	that	cortactin	phosphorylation	at	Y466	was	increased	in	response	to	
APPSWE,	no	causal	relationship	between	Y466	phosphorylation	and	GluA2	lysosomal	targeting	was	
demonstrated.	Future	directions	of	this	work	could	utilise	the	overexpression	of	a	phosphonull	
mutant,	Y466A-cortactin,	to	validate	this.	If	cortactin	phosphorylation	is	indeed	responsible	for	
GluA2	lysosomal	degradation,	this	mutant	should	prevent	the	co-localisation	of	GluA2	with	LAMP1	
and	consequent	degradation.		
It	would	also	be	of	interest	to	determine	the	kinase	responsible	for	aberrant	cortactin	
phosphorylation	during	Aβ	pathogenesis.	A	variety	of	kinases	in	the	SFK	family	have	been	implicated	
in	the	phosphorylation	of	cortactin,	such	as	Fer,	Fyn,	Nck1,	Src	and	Syk	(Wu	and	Parsons,	1993;	Kim	
and	Wong,	1998;	Gallet	et	al.,	1999;	Kapus	et	al.,	2000;	Fan	et	al.,	2004;	Oser	et	al.,	2010).	However,	
Fyn	kinase	is	of	particular	interest	in	this	model	since	it	has	demonstrated	increased	activity	in	
response	to	Aβ	(Lambert	et	al.,	1998;	Chin	et	al.,	2004,	Chin	et	al.,	2005;	Um	et	al.,	2012).	The	robust	
evidence	for	the	aberrant	activation	of	Fyn	in	response	to	amyloidopathy	suggests	that	this	specific	
member	of	the	SFK	family	could	be	responsible	for	the	increased	cortactin	Y466	phosphorylation	in	
the	disease	state.	In	order	to	investigate	this,	aberrant	Fyn	activity	could	be	examined	through	
Western	blotting	for	levels	of	Y416-Fyn	in	response	to	APPSWE	expression,	since	Fyn	is	
phosphorylated	at	this	tyrosine	residue	following	activation	(Um	et	al.,	2012).	Increased	levels	of	
Y416-Fyn	would	indicate	that	Fyn	kinase	might	be	responsible	for	increased	cortactin	
phosphorylation	in	this	model.	Alternatively,	expressing	a	kinase-dead	mutant	of	Fyn	would	
determine	if	the	increase	in	cortactin	Y466	is	blocked.	
7.2.4 Limitations	
	
One	limitation	of	our	antibody	feeding	and	immunocytochemistry	experiments	was	that	appropriate	
controls	were	not	implemented.	These	should	be	carried	out	in	future	experiments	and	include	
primary	antibody	controls	to	confirm	the	specificity	of	the	primary	antibody	binding	to	the	antigen.	
This	can	be	carried	out	by	pre-incubating	the	antibody	with	blocking	peptides,	which	should	
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inactivate	the	antibody	so	that	the	cultures	show	little	or	no	staining	(Burry,	2011).	A	secondary	
antibody	control	should	also	be	carried	out	to	show	that	the	labelling	observed	is	due	only	to	binding	
of	the	secondary	antibody	to	the	primary	antibody.	This	control	can	be	carried	out	by	eliminating	the	
primary	antibody	to	check	for	any	nonspecific	binding,	since	no	labelling	should	be	seen	in	this	
condition	(Burry,	2011).	A	labelling	control	is	an	additional	control	which	should	be	carried	out	by	
examining	cultures	under	the	microscope	under	the	same	conditions	but	with	no	antibodies	to	
demonstrate	the	labelling	is	not	the	result	of	endogenous	labelling	or	reacting	products	(Burry,	
2011).	
Additionally,	it	would	be	advantageous	to	confirm	that	the	AMPAR	complexes	bound	to	antibody	in	
our	experiments	follow	the	same	path	from	the	EE	as	AMPAR	complexes	not	bound	to	antibody.	This	
could	be	done	via	electrophysiology	with	the	use	of	drugs	to	block	lysosomal	targeting,	or	via	
biochemical	techniques	that	involve	fractioning	endosomal	compartments	by	differential	
ultracentrifugation.		
Another	limitation	was	that,	due	to	time	constraints,	western	blotting	experiments	had	to	be	carried	
out	on	cortical	cultures.	Given	a	model	for	the	specific	loss	of	GluA2/3	heteromers	has	previously	
been	proposed	in	response	to	ischaemia	in	hippocampal	but	not	cortical	neurons	involving	a	cell-
type	specific	mechanism,	(Koszegi	et	al.,	2017)	it	would	have	been	ideal	to	carry	out	all	experiments	
in	hippocampal	neuronal	cultures.	However,	our	results	demonstrated	that	a	loss	of	GluA2	
expression	was	demonstrated	in	both	cortical	and	hippocampal	in	vitro	models	of	AD,	indicating	the	
involvement	of	molecular	cell	biology	that	is	common	to	both	cell	types.		
	
7.3 CLINICAL	APPLICATIONS	
	
There	have	been	major	efforts	in	recent	years	to	establish	the	cellular	correlate	of	learning	and	
memory,	with	much	evidence	now	suggesting	that	synaptic	plasticity,	specifically	the	LTP	of	
excitatory	synaptic	transmission	in	the	hippocampus,	is	critical	for	the	formation	of	long-term	
memories	(Morris	et	al.,	1982;	Morris	et	al.,	1986;	Tsien	Huerta	and	Tonegawa,	1996;	Nakazawa	et	
al.,	2002;	Whitlock	et	al.,	2006;	Hunsaker,	Lee	and	Kesner,	2008).	The	major	expression	mechanisms	
of	NMDAR-dependent	LTP	involve	changes	to	the	biophysical	properties	of	AMPARs,	as	well	as	their	
trafficking	to	the	cell	surface	(Derkach,	Barria	and	Soderling,	1999;	Hayashi	et	al.,	2000;	Lee	et	al;	
2000;	Nicoll,	2017;	Diering	and	Huganir,	2018).	It	is	no	surprise	then	that	AD,	now	considered	to	be	
primarily	a	disorder	of	synaptic	failure,	is	characterised	by	cognitive	impairment	which	typically	
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begins	with	memory	deficits	and	eventually	develops	to	incapacitating	levels	(Alzheimer,	1907).	
Indeed,	a	host	of	literature	has	demonstrated	a	role	for	Aβ	in	promoting	the	loss	of	surface	AMPARs	
(Hsieh	et	al.,	2006;	Liu	et	al.,	2010;	Zhao	et	al.,	2010;	Miñano-Molina	et	al.,	2011;	Alfonso	et	al.,	
2014),	which	manifests	as	synaptic	depression	and	deficits	in	learning	and	memory	(Anggono	and	
Huganir,	2012).	Preventing	the	loss	of	these	receptors	is	thus	vital	in	combatting	cognitive	
detriment.	
Indeed,	reducing	processes	that	regulate	AMPAR	ubiquitination	and	degradation	have	already	been	
shown	to	rescue	Aβ-induced	synaptic	deficits	(Rodrigues	et	al.,	2016).	If	cortactin	does	in	fact	
regulate	GluA2-containing	AMPAR	degradation	in	response	to	amyloidopathy,	it	may	prove	to	be	a	
novel	therapeutic	target	to	combat	AMPAR	loss	and	cognitive	decline.	Furthermore,	considering	the	
selective	loss	of	the	GluA2	subunit	from	the	cell	surface	has	been	witnessed	in	other	disease	states	
including	Parkinson’s	disease	(Diogenes	et	al.,	2012;	Cortese	et	al.,	2016)	and	ischaemic	brain	injury	
(Dixon,	Mellor	and	Hanley,	2009;	Blanco-Suarez	and	Hanley,	2014),	investigating	the	role	of	
lysosomal	degradation	and	the	cortactin-AMPAR	interaction	in	these	cases	could	define	a	ubiquitous	
mechanism	responsible	for	AMPAR	loss	across	multiple	neurodegenerative	disorders.		
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